Treatment of medical disorders using CXCR4 inhibitors
Administering CXCR4 inhibitors to fasting patients optimizes pharmacokinetic parameters, effectively increasing neutrophil and lymphocyte counts to treat severe and chronic neutropenia, addressing the limitations of current treatments.
Patent Information
- Application Number
- KR1020267029997
- Authority / Receiving Office
- KR · KR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-13
- Filing Date
- 2025-02-13
- Publication Date
- 2026-11-17
AI Technical Summary
Current treatments for severe and chronic neutropenia, such as G-CSF, are not always effective and can have safety issues, necessitating a more reliable method to increase neutrophil counts and reduce infection risk.
Administering a CXCR4 inhibitor, such as mavorixafor, to fasting patients optimizes pharmacokinetic parameters, enhancing efficacy by increasing neutrophil and lymphocyte counts and duration.
The method significantly increases neutrophil and lymphocyte counts, reducing infection risk and potentially reducing G-CSF dosage or eliminating its need, while being safer for patients with congenital or chronic neutropenia.
Smart Images

Figure P1020267029997_ABST
Abstract
Description
Technology Field
[0001] related In the application Korea Mutual reference
[0002] This application claims the benefit and priority of U.S. Provisional Application No. 63 / 553,001 filed on February 13, 2024, the entire contents of which are incorporated herein by reference.
[0003] invention field
[0004] The present invention relates to a method for treating leukocytopenia, such as severe chronic idiopathic neutropenia and certain genetically defined congenital forms of neutropenia, by using a compound that inhibits CXC receptor type 4 (CXCR4) administered after the patient has fasted. Background Technology
[0005] Neutropenia is a condition characterized by an abnormally low concentration of circulating neutrophils in the blood, defined as an absolute neutrophil count (ANC) of less than 1,500 cells / μL. Severe neutropenia (ANC <500 cells / μL) is a risk factor associated with susceptibility to bacterial infections. Neutrophils constitute the majority of circulating white blood cells and play a crucial role in the body's defense against infections caused by bacterial or fungal pathogens and in the formation of the host response to infection. Additionally, neutrophils are involved in the homeostasis of the immune system. Neutropenia can be classified into congenital (i.e., present at birth) and acquired types. In addition, neutropenia can be "acute" (transient or temporary, often occurring as a response to specific events that deplete the body's neutrophils, such as radiation or chemotherapy) or "chronic" (long-term or prolonged effects that may occur due to the presence of genetic abnormalities).
[0006] Acute or transient neutropenia is caused by the bacterium that causes typhoid fever Salmonella enterica It can be caused by infectious agents such as ; and cytomegalovirus, as well as chemical agents including propylthiouracil; levamisole; penicillamine; clozapine; valproic acid; and cancer chemotherapy.
[0007] Chronic neutropenia can be caused by genetic abnormalities (congenital neutropenia). ELANE Mutations in [it] are the most common cause of congenital neutropenia. Examples of other genes that can be genetic causes of neutropenia include HAX1, G6PC3, WAS, SBDSThese include, etc. Additionally, some enzyme deficiencies, such as glycogen storage disease 1b, may be associated with neutropenia. Other causes of neutropenia include mitochondrial diseases such as Pearson syndrome. Some autoimmune diseases, such as systemic lupus erythematosus (“SLE” or “lupus”), may be associated with neutropenia. Aplastic anemia due to bone marrow failure is associated with thrombocytopenia, anemia, and neutropenia; Evans syndrome is characterized by autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) and / or immune neutropenia; Felty's syndrome is characterized by rheumatoid arthritis, splenomegaly, and neutropenia. Chronic neutropenia may also be the result of nutritional deficiencies, such as abnormally low levels of copper or vitamin B12; or chronic infections, such as infection by the human immunodeficiency virus (HIV), the pathogen that causes AID syndrome.
[0008] Neutropenia can be asymptomatic and is often diagnosed only incidentally. Currently, the standard treatment for severe neutropenia is the administration of granulocyte colony-stimulating factor (G-CSF). Historically, neutropenia has been treated in various ways, including splenectomy, corticosteroids, androgens, immunosuppressive therapy, and immunomodulatory therapy. However, these treatments are currently generally not recommended except in cases where treatment with G-CSF is ineffective. Dale et al. (2017) Curr. Opin. Hematol. 24:46-53; Sicre de Fontbrune et al. (2015) Blood 126:1643-1650. Other treatments for neutropenia may include bone marrow transportation and / or therapy using umbilical cord blood stem cells.
[0009] Effective treatment is still needed for severe and chronic neutropenia, in particular, which leads to an increased risk of infection and other disorders. The present invention meets this need and provides other related benefits. Brief explanation of the drawing
[0010] Figure 1 shows the C of mavorixafor in healthy volunteers. max It shows the effects of eating and fasting status on. Figure 2 shows the AUC of Maborixapor in healthy volunteers (0-inf) It shows the effects of eating and fasting status on. Specific details for implementing the invention
[0011] Administering CXCR4 inhibitors with or without G-CSF has been shown to be useful in treating neutropenia. Now, peak serum concentration (C maxIt has been revealed that the efficacy of CXCR4 inhibitors can be significantly improved by optimizing pharmacokinetic (PK) parameters such as ). For example, administering a CXCR4 inhibitor to a fasting patient provides an optimized PK profile and enhanced efficacy. Accordingly, the present invention provides a fasting profile for a patient with lymphocytopenia (e.g., leukopenia or neutropenia) treated with a CXCR4 inhibitor.
[0012] It has now been revealed that administration regimens (e.g., fasting requirements) can help optimize the PK profile and consequent efficacy of CXCR4 inhibitors in the treatment of neutropenia. Chronic neutropenia can be congenital or acquired, and acquired forms include primary and secondary neutropenias. Primary neutropenia includes idiopathic (by definition, idiopathic means that all other causes have been excluded); and neutropenia induced by autoimmune and alloimmunological factors, etc. Secondary neutropenia is most commonly attributed to hypersplenism as well as the effects of drugs such as chemotherapy. Chronic congenital neutropenia includes specific genetically defined congenital forms of neutropenia, including those disclosed herein.
[0013] As used herein, the term "neutropenia" means that a patient has an absolute neutrophil count (ANC) of about 1500 cells / μL or less. Neutropenia treated according to the disclosed method includes mild, moderate, and severe neutropenia. "Mild neutropenia" is generally described as a patient having an ANC of 1000 to 1500 cells / μL. "Moderate neutropenia" is understood to refer to a patient having an ANC of 500 to 1500 cells / μL. As used herein, "severe neutropenia" means that a patient has an ANC of 500 cells / μL or less. Beneficial treatment may include treatment that significantly increases the patient's neutrophil count even if the patient remains in a 'neutropenic' state with an ANC <1500 cells / μL. For example, a patient with severe neutropenia [ANC < 500 cells / μL] may be treated using the method of the present invention until the patient's ANC rises to 1000 cells / μL. In the professional judgment of the treating physician, this result may be considered a successful treatment, but the patient will continue to be characterized as having mild to moderate neutropenia.
[0014] The term "chronic neutropenia" as used herein is defined as neutropenia that persists for a period of at least 3 months. The term "idiopathic" applied to neutropenia here means that all other causes have been ruled out, for example, that the patient's neutropenia is not attributable to drugs or any specifically identified hereditary, infectious, inflammatory, autoimmune, or malignant cause.
[0015] The condition referred to as "congenital neutropenia" at our institution is caused by a mutation in the ELANE gene, which is one of the most common causes of congenital neutropenia. ELANE Genetically defined mutations such as, SLC37A4Glycogen storage disease type 1b (GSD1b) caused by a mutation, G6PC3 Deficiency of glucose-6-phosphatase catalytic subunit 3 (G6PC3) due to a mutation; or GATA2 Includes patients exhibiting neutropenia (or severe neutropenia) due to a deficiency of GATA-binding protein 2 (GATA2) caused by a mutation. Other genetically defined conditions without arrest of myeloid maturation at the myeloid / promyeloid stage are also included in this definition.
[0016] The terms "cyclic neutropenia" or "cyclical neutropenia" as used herein may be used interchangeably and refer to a rare hematological condition in which a patient typically exhibits regular fluctuations in blood neutrophil counts and cyclic neutropenia occurs in a cycle of approximately 21 days. During a cycle, severe neutropenia typically lasts for 3 to 6 days. The cycle generally remains constant and consistent in affected individuals. Additionally, abnormal levels of red blood cells (anemia), changes in levels of blood components that aid in clotting (platelets), the presence of immature red blood cells (reticulocytes), and cyclic changes in other white blood cells may occur. A feature that almost always appears is an increase in blood monocytes at the trough of the neutrophil cycle. The diagnosis of cyclic neutropenia is based on a detailed patient history and a thorough clinical evaluation. Diagnosis can be confirmed by monitoring the individual's neutrophil count two or three times a week for six weeks. Individuals with cyclic neutropenia ELANE Genetic testing for gene mutations must be performed. In some embodiments of the present invention, the patient to be treated has cyclic neutropenia. In some embodiments, the patient ELANE It has a mutation.
[0017] chronic idiopathic Chronic Idiopathic Neutropenia (CIN), severe chronic Severe Chronic Neutropenia (SCN), Cyclic Cyclical Neutropenia (CyN) and autoimmune Autoimmune Neutropenia (AIN) and same Neutropenia
[0018] Chronic neutropenia is defined as neutropenia persisting for at least three months. The term "idiopathic" indicates that the neutropenia is not attributable to drugs or identified hereditary, infectious, inflammatory, autoimmune, or malignant causes. Therefore, the diagnosis of chronic idiopathic neutropenia (CIN) is made by excluding other causes. Finally, neutropenia is considered "severe" if the absolute neutrophil count (ANC) is less than 500 cells / μL. Furthermore, because it is difficult to accurately detect circulating antibodies against antigens present on the surface of neutrophils and difficult to clinically interpret the results of anti-neutrophil antibody tests, there is overlap between patients diagnosed with CIN and those diagnosed with "autoimmune neutropenia" (AIN) (Dale, Current Opin Hematol, 2018). The estimated adult prevalence of severe chronic idiopathic neutropenia is approximately 5 per million people (Dale and Bolyard (2017) Curr. Opin. Hematol. 24:46-53). CIN is more common in women (Kyle and Linman (1968) N. Engl. J. Med. 279:1015-1019). Different pathophysiological mechanisms have been identified, including decreased neutrophil production, increased peripheral clearance, and excessive demarcation (Greenberg et al. (1980) Blood 55:915-921). A neutrophil count of less than 500 cells / μL is associated with an increased risk of infection. In one study, bone marrow was analyzed in approximately one-third of a patient group of 108, and the results were normal in 34% of patients; late maturation arrest was observed in 31% of patients; and granulocyte hypoplasia was observed in 15% of patients; Cytoplasmicity increased in 20% of patients (Sicre de Fontbrune 2015). A randomized controlled trial of G-CSF for the treatment of severe chronic neutropenia involving 42 patients with CIN established that G-CSF is an effective therapy for this condition (Dale (1993) Blood 81:2496-2502).
[0019] In some embodiments, treating a specific patient subgroup with a CXCR4 antagonist (e.g., maborixafor or a pharmaceutically acceptable salt thereof) is particularly effective.
[0020] In some embodiments, the patient is male. In some embodiments, the patient is female.
[0021] In some embodiments, the patient is under 50 years of age. In some embodiments, the patient is at least 50 years of age.
[0022] In some embodiments, the patient was previously treated with G-CSF. In some embodiments, the patient was previously treated with G-CSF but is not currently receiving G-CSF.
[0023] It should be understood that the G-CSF used in this institution may be replaced with variants of G-CSF, such as pegylated G-CSF (peg-filgrastim) or GM-CSF.
[0024] In some embodiments, maborixaphor or a pharmaceutically acceptable salt thereof and G-CSF or another granulocyte colony-stimulating factor treatment, such as that described herein, have a synergistic effect. The synergistic effect includes, for example, more effective treatment of the disease than using either agonist alone; or providing effective treatment of the disease with a lower dose of one or both agonists than when using either agonist alone.
[0025] In some embodiments, maborixaphor and G-CSF act additionally or synergistically.
[0026] In some embodiments, treatment with a CXCR4 antagonist is effective in increasing lymphocytes. In some embodiments, treatment with a CXCR4 antagonist has a beneficial effect on lymphocytes (particularly B-cells and T-cells). In some embodiments, treatment with a CXCR4 antagonist has a beneficial effect on adaptive immune responses. In some embodiments, treatment with a CXCR4 antagonist is effective in treating infection frequency, severity, and / or duration of infection.
[0027] In some embodiments, the patient was not treated with G-CSF before starting treatment with maborixafor or its pharmaceutically acceptable salt.
[0028] In some embodiments, as further discussed below, the patient is currently being treated with G-CSF. In some embodiments, after treatment with mavorixafor or a pharmaceutically acceptable salt thereof is initiated, the dose and / or frequency of G-CSF administration is reduced while maintaining the efficacy of the therapeutic regimen. In some embodiments, after treatment with mavorixafor or a pharmaceutically acceptable salt thereof is initiated, treatment with G-CSF is completely discontinued (while maintaining effective treatment for the patient's neutropenia).
[0029] In some embodiments, the patient is effectively treated with a CXCR4 antagonist such as maborixafor, and G-CSF dose adjustment is performed while maintaining effective treatment of the patient's infection frequency, severity, and / or duration of infection.
[0030] In some embodiments, the patient has idiopathic neutropenia. In some embodiments, the patient has severe idiopathic neutropenia. In some embodiments, the patient has chronic neutropenia. In some embodiments, the patient has SCN, CIN, or AIN. In some embodiments, the patient underwent genetic testing but no diagnosis of genetic abnormality was made. In some embodiments, no conclusion could be drawn from the genetic test results. In some embodiments, the genetic test revealed no known genetic abnormalities or genetic abnormalities not associated with neutropenia. In some embodiments, the patient has neutropenia caused by one or more of infectious, inflammatory, autoimmune, or malignant causes, rather than genetic abnormalities. In some embodiments, the malignant cause is cancer.
[0031] In some embodiments, the patient has severe congenital neutropenia, suspected aplastic anemia, B-cell immunodeficiency, juvenile myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia, a severe Epstein-Barr virus infection or Epstein-Barr-associated cancers, B-cell acute lymphoblastic leukemia or unexplained bone marrow failure.
[0032] In some embodiments, the patient has undergone genetic testing and has been diagnosed with a genetic abnormality other than that associated with WHIM syndrome. In some embodiments, the patient has congenital neutropenia. In some embodiments, the patient has a genetic abnormality selected from GSD1b, G6PC3 deficiency, GATA2 deficiency, a genetically defined condition without arrest of myeloid maturation at the myeloid / promyeloid stage, or an undefined genetic abnormality.
[0033] In some embodiments, patients treated with G-CSF have experienced safety and tolerability issues (e.g., bone pain, muscle pain, etc.) and / or the treating physician determines that there is a significant risk of malignant transformation in patients with congenital neutropenia. In some embodiments, the treating clinician determines that any of the above safety and tolerability issues will be reduced by adding treatment with a CXCR4 antagonist, such as maborixafor, in combination with a reduction in the patient's G-CSF dose and / or frequency.
[0034] G6PC3 lack
[0035] G6PC3 The gene encodes G6PC3, which is expressed locally. In 2009, Boztug showed that the effective function of G6PC3 underlies severe congenital neutropenia syndrome associated with cardiac and genitourinary malformations (Boztug et al. (2009) N Engl J Med. 360:32-43).
[0036] As of 2013, 57 patients with G6PC3 deficiency have been described in the literature (Banka and Newman (2013) Orphanet J Rare Dis. 8:84). Globally, 91 cases have been reported, with an estimated incidence of 0.4 per 1,000,000 births, and the reported cases are primarily of Turkish, Pakistani, and French descent. G6PC3 deficiency typically manifests as recurrent bacterial infections during the first few months of life and ANC levels ranging from 120 to 550 cells / μL (McDermott et al. (2010) Blood. 116:2793-802). The first severe infection can occur at any age from immediately after birth to adulthood (Banka (2015, in Gene Reviews, Adam et al, editors. University of Washington, Seattle; 1993–2019). Common reported bacterial infections include respiratory tract infections, otitis media, stomatitis, urinary tract infections, pyelonephritis, skin abscesses, cellulitis, and sepsis. G6PC3 deficiency varies in severity and associated clinical features. It may manifest as a non-syndromic form with only severe congenital neutropenia, or more commonly as a syndromic form with cardiovascular and / or genitourinary features. A subgroup of patients with the syndromic disease exhibits a severe form (Dursun syndrome) due to the additional involvement of myeloid cells, which occurs in the neonatal period. It is characterized by primary pulmonary hypertension and mild atypical features (Banka 2015).It is estimated that nearly 10% of G6CP3 deficiencies are in the non-syndromic form, but this may be an underestimation due to confirmation bias (i.e., selecting more severe phenotypes for G6PC3 testing in previous studies) (Banka 2013). Some patients who initially present in the non-syndromic form may develop features of the classical form later in life (Banka 2015). While bone marrow analysis may reveal arrest of myeloid lineage maturation, other G6PC3 deficient patients may have hypercellular or normocellular bone marrow (McDermott 2010; Banka et al. (2011) Am J Hematol. 86:235-7).
[0037] GATA2 lack
[0038] GATA2 deficiency is GATA2 It is an autosomal dominant bone marrow failure disorder with systemic characteristics caused by a heterozygous germline mutation in one of the two copies of the GATA2 gene encoding a protein. Germline GATA2 Mutations were detected in patients with severe congenital neutropenia, suspected aplastic anemia, B-cell immunodeficiency, pediatric myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia, severe Epstein-Barr virus infection and Epstein-Barr-associated cancer, B-cell acute lymphoblastic leukemia, and other cases of bone marrow failure of unknown etiology (Crispino and Horwitz (2017) Blood. 129:2103-10). In 2017 and 2018, 457 cases of GATA2 deficiency were reported worldwide. Patients have varying ANC levels of 1,100 to 8,460 cells / μL (Maciejewski-Duval et al. (2016) J Leukoc Bio. 99:1065-76) and commonly 112 to 1,987 cells / μL (Vinh et al. (2010) Blood. 115:1519-29) or 490 to 2,900X10 6It exhibited low lymphocyte levels of / mL (Maciejewski-Duval 2016). Bone marrow in patients with GATA2 deficiency has been reported to vary from hypocellular bone marrow with normal cytogenetic findings to hypercellular bone marrow with poor cytogenetic findings, and to overt AML with 85% mononuclear cells (Hickstein (2018) Blood. 131:1272-74). The GATA 2 deficiency phenotype varies from immunodeficiency to aplastic anemia, MDS, and leukemia (Hickstein 2018).
[0039] GATA2 germline mutations GATA2 While acquired mutations induce deficiency, diagnosis is more difficult because they are observed in the transition to the blastocyst crisis of MDS, AML, and chronic myeloid leukemia. Indeed, GATA2 deficiency is currently the most common hereditary cause of MDS in children and adolescents. The natural course of GATA2 deficiency varies significantly even among individuals with the same mutation. Infectious complications are common in GATA2 deficiency and arise from a selective cellular deficiency profile, namely the deficiency of monocytes, natural killer cells, and B lymphocytes. The hematological manifestation of GATA2 deficiency is primarily progressive cytopenia, which can progress from normal cell bone marrow to hypocellular MDS or AML.
[0040] Approximately half of patients with GATA2 deficiency undergo allogeneic hematopoietic stem cell transplantation (Hickstein 2018), and allogeneic stem cell transplantation is the only curative treatment for GATA2 deficiency. Asymptomatic GATA2There are no clear guidelines regarding patient monitoring schedules or ideal prophylactic regimens. However, suggestions include monitoring peripheral blood cell counts every 3 to 6 months, performing a bone marrow biopsy with cytogenetics every 1 to 2 years, and transplanting before severe end-organ injury or leukemia develops (Hsu et al. (2015) Curr. Opin. Allergy Clin. Immunol. 15:104-9).
[0041] CXCR4 inhibitors (e.g., mavoric saporn) can serve as a useful bridge to transplantation because they have the potential to improve both neutropenia and lymphopenia in these patients.
[0042] patient fasting Accompanied CXCR4 inhibitors used Neutropenia therapy method
[0043] Without wishing to be bound by theory, fasting before administering CXCR4 inhibitors to a patient [regarding] their PK characteristics (e.g., increased C max It is believed that ) is enhanced, resulting in increased efficacy (e.g., increased neutrophil count compared to administration without fasting) and / or increased duration of the elevated neutrophil count ("Time Above Threshold" or "TAT-ANC"). Additionally, it is believed that this method may result in an increase in lymphocyte count ("ALC") and / or increased duration of the elevated lymphocyte count ("Time Above Threshold" or "TAT-ALC").
[0044] In some embodiments, TAT-ANC is about 15 hours. In some embodiments, TAT-ANC is about 15-18 hours. In some embodiments, TAT-ANC is about 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, or 20 hours. In some embodiments, TAT-ANC is about 13-20, 13.5-20, 14-20, 14.5-20, 15-20, 15.5-20, 16-20, 16.5-20, 17-20, 17.5-20, 18-20, 18.5-20, 19-20, or 19.5-20 hours. In some embodiments, TAT-ANC is about 13-19, 13.5-19, 14-19, 14.5-19, 15-19, 15.5-19, 16-19, 16.5-19, 17-19, 17.5-19, 18-19, or 18.5-19 hours. In some embodiments, TAT-ANC is about 13-18, 13.5-18, 14-18, 14.5-18, 15-18, 15.5-18, 16-18, 16.5-18, 17-18, or 17.5-18 hours. In some embodiments, TAT-ANC is about 13-17, 13.5-17, 14-17, 14.5-17, 15-17, 15.5-17, 16-17, or 16.5-17 hours.
[0045] In some embodiments, TAT-ALC is about 15 hours. In some embodiments, TAT-ALC is about 15-18 hours. In some embodiments, TAT-ALC is about 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, or 20 hours. In some embodiments, TAT-ALC is about 13-20, 13.5-20, 14-20, 14.5-20, 15-20, 15.5-20, 16-20, 16.5-20, 17-20, 17.5-20, 18-20, 18.5-20, 19-20, or 19.5-20 hours. In some embodiments, TAT-ALC is about 13-19, 13.5-19, 14-19, 14.5-19, 15-19, 15.5-19, 16-19, 16.5-19, 17-19, 17.5-19, 18-19, or 18.5-19 hours. In some embodiments, TAT-ALC is about 13-18, 13.5-18, 14-18, 14.5-18, 15-18, 15.5-18, 16-18, 16.5-18, 17-18, or 17.5-18 hours. In some embodiments, TAT-ALC is about 13-17, 13.5-17, 14-17, 14.5-17, 15-17, 15.5-17, 16-17, or 16.5-17 hours.
[0046] PK / PD Regarding the parameters argument
[0047] PK / PD parameters :
[0048] Cmax - The maximum concentration of a therapeutic agent detected in plasma after administration of a therapeutic agent (e.g., a CXCR4 inhibitor).
[0049] Tmax - Time at which Cmax is observed after administration.
[0050] Tlast - The time after administration when the therapeutic agent is last detectable in plasma.
[0051] Tlag- Time delay or phase of up to 10% from the time of intake.
[0052] T 1 / 2 - The time after administration of the therapeutic agent until the concentration becomes equal to ½ of the concentration immediately after administration (or ½ of Cmax).
[0053] AUC - Area under the curve - This is the total area under the concentration curve of a therapeutic agent (or other parameter) detected in plasma over a certain period. It measures the total amount of the therapeutic agent (or other parameter) over a certain period after administration.
[0054] ANC-max
[0055] ALC-max
[0056] TAT-ANC = "Time over threshold" - The time during which the ANC measurement remains higher than the target threshold neutrophil concentration after administration of the therapeutic agent.
[0057] TAT-ALC = "Time over threshold" - The time during which the ALC measurement remains higher than the target critical lymphocyte concentration after administration of the therapeutic agent.
[0058] Accordingly, in one aspect, the present disclosure provides a method for treating neutropenia in a patient, said method comprising the step of orally administering a CXCR4 inhibitor or a pharmaceutically acceptable salt thereof to a patient, wherein the patient has fasted from all food and beverages except water for at least 7 hours prior to administration of the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof and has continued fasting for at least 30 minutes after administration; and the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof is administered once daily at a dose of about 100 mg to about 800 mg. In another aspect, the present disclosure provides a method for treating lymphopenia in a patient, said method comprising the step of orally administering a CXCR4 inhibitor or a pharmaceutically acceptable salt thereof to a patient, said method comprising the step of fasting from all food and beverages except water for at least 7 hours prior to administration of the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof and has continued fasting for at least 30 minutes after administration; A CXCR4 inhibitor or a pharmaceutically acceptable salt thereof is administered once daily at a dose of about 100 mg to about 800 mg.
[0059] In some embodiments, when the patient's age and / or weight is low (e.g., < about 50 kg), the method of the present invention may further include the step of administering a lower dose of a CXCR4 inhibitor. For example, a lower dose of about 50 mg to about 100 mg may be administered daily to a patient aged 6 to 11 years; and a lower dose of about 25 mg to about 100 mg may be administered daily to a patient aged 2 to 5 years. For example, the daily dose may be about 25 mg to about 50 mg, e.g., about 25 mg, about 50 mg, about 75 mg, or about 100 mg.
[0060] In some embodiments, the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof is mavorixapor or a pharmaceutically acceptable salt thereof. It should be understood that in any of the methods described herein, the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof may be a CXCR4 inhibitor other than mavorixapor or a pharmaceutically acceptable salt thereof. The CXCR4 inhibitor includes those described herein.
[0061] In some embodiments, the present disclosure provides a method for treating neutropenia in a patient, the method comprising the step of orally administering mavorixafor or a pharmaceutically acceptable salt thereof to the patient, wherein the patient has fasted from all food and beverages except water for at least 7 hours prior to administration of mavorixafor or a pharmaceutically acceptable salt thereof and has continued to fast for at least 30 minutes after administration; and mavorixafor or a pharmaceutically acceptable salt thereof is administered once daily in a dose of about 100 mg to about 800 mg. If the patient is young or weighs less than about 50 kg, mavorixafor or a pharmaceutically acceptable salt thereof is administered once daily in a dose of about 25 mg to about 100 mg.
[0062] In some embodiments, maborixafor or a pharmaceutically acceptable salt thereof is about 100 mg to about 800 mg; about 100 mg to about 700 mg; about 100 mg to about 600 mg; about 100 mg to about 500 mg; about 100 mg to about 400 mg; about 100 mg to about 300 mg; about 100 mg to about 200 mg; 200 mg to about 800 mg; about 200 mg to about 700 mg; about 200 mg to about 600 mg; about 200 mg to about 500 mg; about 200 mg to about 400 mg; about 200 mg to about 300 mg; 300 mg to about 800 mg; about 300 mg to about 700 mg; about 300 mg to about 600 mg; It is administered once a day in a dose of about 300 mg to about 500 mg; about 300 mg to about 400 mg; about 400 mg to about 800 mg; about 400 mg to about 700 mg; about 400 mg to about 600 mg; about 400 mg to about 500 mg; about 500 mg to about 800 mg; about 500 mg to about 700 mg; about 500 mg to about 600 mg; about 600 mg to about 800 mg; about 600 mg to about 700 mg; or about 700 mg to about 800 mg. In some embodiments, Maborixapor is administered once a day at a dose of about 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, or 800 mg.
[0063] In the method described herein, the dose of maborixaphor may vary depending on the patient's age and / or weight. For example, in some embodiments, the patient is at least 18 years of age. In some embodiments, the patient is 12 to 17 years of age and weighs at least 50 kg. In some embodiments, the patient is 12 to 17 years of age and weighs less than 50 kg. In some embodiments, the patient is 6 to 11 years of age or 6 to 12 years of age. In some embodiments, the patient is 2 to 5 years of age or 2 to 6 years of age.
[0064] In some embodiments, if the patient is at least 18 years of age, the patient is administered about 400 mg of mavorixafor or a pharmaceutically acceptable salt thereof per day; if the patient is 12 to 17 years of age and weighs at least 50 kg, the patient is administered about 400 mg of mavorixafor or a pharmaceutically acceptable salt thereof per day; if the patient is 12 to 17 years of age and weighs less than 50 kg, the patient is administered about 200 mg of mavorixafor or a pharmaceutically acceptable salt thereof per day.
[0065] In some embodiments, the patient is at least 12 years old. In some embodiments, the patient is at least 18 years old. In some embodiments, the patient is 12 to 17 years old. In some embodiments, the patient is 18 to 30 years old, 18 to 40 years old, 18 to 50 years old, 18 to 60 years old, 18 to 70 years old, 30 to 40 years old, 30 to 50 years old, 30 to 60 years old, 30 to 70 years old, 40 to 50 years old, 40 to 60 years old, 40 to 70 years old, 50 to 60 years old, 50 to 70 years old, 60 to 70 years old. In some embodiments, the patient is over 70 years old.
[0066] In addition, in any of the methods described herein, the fasting period before or after administration of a CXCR4 inhibitor (e.g., maborixafor) may be increased or decreased depending on the patient.
[0067] In some embodiments, the patient fasted for at least 8 hours before administration of maborixafor or a pharmaceutically acceptable salt thereof. In some embodiments, the patient fasted for at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, or at least 16 hours before administration of maborixafor or a pharmaceutically acceptable salt thereof.
[0068] In some embodiments, the patient fasted for 7 to 16 hours prior to administration of maborixafor or a pharmaceutically acceptable salt thereof. In certain embodiments, the patient fasted for 7 to 14, 7 to 12, 7 to 10, 7 to 9, 8 to 16, 8 to 14, 8 to 12, 8 to 10, 10 to 16, 10 to 14, 10 to 12, 12 to 16, 12 to 14, or 14 to 16 hours prior to administration of maborixafor or a pharmaceutically acceptable salt thereof.
[0069] In any of the methods described herein, it may be advantageous for the patient to continue fasting after administration of a CXCR4 inhibitor (e.g., mavorixafor). For example, in some embodiments, the patient continues fasting for at least 30 minutes, at least 45 minutes, at least 1 hour, at least 1.5 hours, or at least 2 hours after administration. In certain embodiments, the patient continues fasting for 30 minutes to 4 hours after administration. In some embodiments, the patient fasts for 30 minutes to 4 hours, 30 minutes to 3.5 hours, 30 minutes to 3 hours, 30 minutes to 2.5 hours, 30 minutes to 2 hours, 30 minutes to 1.5 hours, 30 minutes to 1 hour; Fasting continues for 1 to 4 hours, 1 to 3.5 hours, 1 to 3 hours, 1 to 2.5 hours, 1 to 2 hours, 1 to 1.5 hours, 1.5 to 4 hours, 1.5 to 3.5 hours, 1.5 to 3 hours, 1.5 to 2.5 hours, 1.5 to 2 hours, 2 to 4 hours, 2 to 3.5 hours, 2 to 3 hours, 2 to 2.5 hours, 2.5 to 4 hours, 2.5 to 3.5 hours, 2.5 to 3 hours, 3 to 4 hours, or 3.5 to 4 hours.
[0070] In some embodiments, the first meal consumed after administration of the CXCR4 inhibitor is a high-fat meal (e.g., 40-60% fat content, e.g., about 50% fat content; in some embodiments, the high-fat meal is also high-calorie and is defined as consisting of about 800 to about 1000 calories). In some embodiments, in the high-fat meal, about 150, 250, and 500-600 calories are derived from protein, carbohydrates, and fat, respectively. In some embodiments, the first meal consumed after administration of the CXCR4 inhibitor is a moderate-fat meal (e.g., 30-40% fat content, e.g., about 35% fat content; in some embodiments, the moderate-fat meal is about 600 to <800 calories). In some embodiments, the first meal consumed after administration of the CXCR4 inhibitor is a low-fat meal (e.g., fat content 10 to <30%, e.g., about 20% fat; in some embodiments, the low-fat meal is about 300 to <600 calories).
[0071] As described above, neutropenia may be characterized by the patient's absolute neutrophil count (ANC) prior to treatment. In some embodiments of the method disclosed herein, the patient has an absolute neutrophil count (ANC) of less than 1,500 cells / μL that has persisted for at least 3 months prior to initiating treatment with mavorixafor or a pharmaceutically acceptable salt thereof. In some embodiments, the patient has an absolute neutrophil count (ANC) of less than 1,000 cells / μL that has persisted for at least 3 months prior to initiating treatment with mavorixafor or a pharmaceutically acceptable salt thereof. In some embodiments, the patient has an absolute neutrophil count (ANC) of less than 600 cells / μL that has persisted for at least 3 months prior to initiating treatment with mavorixafor or a pharmaceutically acceptable salt thereof. In some embodiments, the patient has an absolute neutrophil count (ANC) of less than 500 cells / μL prior to initiating treatment with mavorixafor or a pharmaceutically acceptable salt thereof. In some embodiments, the patient has an absolute neutrophil count (ANC) of less than 400 cells / μL before starting treatment with maborixafor or a pharmaceutically acceptable salt thereof.
[0072] In some embodiments, the patient has an ANC of less than 300 cells / μL, less than 200 cells / μL, or less than 100 cells / μL before starting treatment. In some embodiments, the patient has an ANC of about 100-1500 cells / μL, about 100-1000 cells / μL, about 100-600 cells / μL, about 100-500 cells / μL, about 500-1500 cells / μL, about 500-1000 cells / μL, about 500-600 cells / μL, about 600-1500 cells / μL, about 600-1000 cells / μL, or about 1000-1500 cells / μL before starting treatment.
[0073] In some embodiments, the patient had neutropenia for at least 1 month, at least 2 months, at least 3 months, at least 6 months, at least 9 months, at least 1 year, at least 1.5 years, at least 2 years, at least 2.5 years, or at least 3 years prior to starting treatment. In some embodiments, the patient was previously treated for neutropenia. In some embodiments, the patient is currently receiving treatment for neutropenia. In some embodiments, the patient was not previously treated for neutropenia. In some embodiments, the patient is not currently receiving treatment for neutropenia.
[0074] The method described herein may be suitable for treating patients with neutropenia of any degree. For example, in some embodiments, the patient has mild neutropenia (e.g., ANC ≥ 1000 - < 1500 cells / μL). In some embodiments, the patient has moderate neutropenia (e.g., ANC ≥ 500 - < 1000 cells / μL). In some embodiments, the patient has severe neutropenia (e.g., ANC < 500 cells / μL). In some embodiments, the patient has chronic neutropenia (e.g., ANC < 1500 cells / μL lasting for 3 months or more).
[0075] As described above, there are multiple etiologies of neutropenia. The methods described herein may be useful for treating neutropenia of various origins, including those specifically described herein. In some embodiments, the patient has congenital neutropenia. In some embodiments, the patient has acquired neutropenia. In some embodiments, the patient has ELANE-related congenital neutropenia. In some embodiments, the patient has CSF3R-related congenital neutropenia. In some embodiments, the patient has HAX1-related congenital neutropenia. In some embodiments, the patient has CXCR4-related congenital neutropenia. In some embodiments, the neutropenia is associated with the manifestation of extrahematological symptoms selected from Barth syndrome, Cohen syndrome, G6PC3, and Kostmann disease; or is associated with glycogen storage disease 1b (GSD1b). In some embodiments, neutropenia is associated with one or more metabolic disorders. In some embodiments, neutropenia is associated with Schwachman-Diamond syndrome. In some embodiments, neutropenia is associated with Cohen syndrome. In some embodiments, neutropenia is associated with GSD1b / Von Gierke disease. In some embodiments, neutropenia is associated with Pearson syndrome. In some embodiments, neutropenia is associated with Schimke immune-osseus dysplasia. In some embodiments, neutropenia is associated with Specific Granule Deficiency. In some embodiments, neutropenia is associated with Wolcott-Rallison syndrome. In some embodiments, neutropenia is cyclic neutropenia.
[0076] In some embodiments, the patient has severe congenital neutropenia (SCN) before starting treatment with mavorixafor or a pharmaceutically acceptable salt thereof. In some embodiments, the patient has chronic idiopathic neutropenia (CIN) before starting treatment with mavorixafor or a pharmaceutically acceptable salt thereof.
[0077] In some embodiments, neutropenia is an SCN associated with ELANE, CSF3R, CXCR2, or WAS mutations.
[0078] In some embodiments, the patient has a GATA2 deficiency. In some embodiments, the patient has a genetically defined condition in which there is no arrest of myeloid maturation at the myeloid / promyeloid stage.
[0079] In some embodiments, the patient has genetically defined chronic neutropenia associated with a gene selected from AK2, AP3B1, CD40LG, CEBPE, CLPB, CSF3R, CXCR2, EIF2AK, ELANE / ELA2*, G6PC3, GATA2, GFI1, HAX1, JAGN1, LAMTOR2, LCP1, LYST, RAB27A, RMRP, SARCAL1, SEC61A1, SLC37A4, SMARCD2, SRP54, STK4, TAZ, TCIRG1, TCN2, VPS13B, VPS45, or WAS. It should be understood that neutropenia may be associated with any number of genetic variations, including any combination of any of the foregoing.
[0080] In some embodiments, patients have congenital neutropenia, acquired primary autoimmune neutropenia, or chronic idiopathic neutropenia before starting treatment with maborixafor or a pharmaceutically acceptable salt thereof. In some embodiments, the patient has congenital neutropenia. In some embodiments, the patient has primary acquired neutropenia. In some embodiments, the primary acquired neutropenia is primary autoimmune neutropenia. In some embodiments, the primary acquired neutropenia is idiopathic.
[0081] In some embodiments, neutropenia is not due to medications the patient is currently taking or has taken. In some embodiments, neutropenia is not due to an active or recent infection. In some embodiments, neutropenia is not due to a malignant tumor.
[0082] In some embodiments, the patient has an increased risk of infection selected from respiratory infection, otitis media, stomatitis, urinary tract infection, pyelonephritis, skin abscess, cellulitis, and sepsis before starting treatment.
[0083] In some embodiments, the patient experienced at least 7 infections over the past year. In some embodiments, the patient experienced at least 2 infections requiring hospitalization over the past year. In some embodiments, the patient experienced at least 7 infections over the past year and at least 2 infections requiring hospitalization over the past year.
[0084] The method described herein may be useful for improving the outcome of an infection. For example, in some embodiments, the method results in an improvement in the frequency, severity, duration, or time to the next infection of the infection; the occurrence and / or disappearance of oral ulcers; the appearance and / or disappearance of gingivitis; or any combination of the foregoing.
[0085] As described above, the method disclosed herein is useful for increasing a patient's absolute neutrophil count (ANC) or absolute leukocyte count (ALC) compared to before treatment. For example, in some embodiments, the method achieves an ANC of at least 500 cells / μL and / or an absolute leukocyte count ALC of at least 1000 cells / μL. In some embodiments, the method achieves about 500 cells / μL to 3000 cells / μL; about 1000 cells / μL to 3000 cells / μL; about 1500 cells / μL to 3000 cells / μL; about 2000 cells / μL to 3000 cells / μL; about 2500 cells / μL to 3000 cells / μL; about 500 cells / μL to 2500 cells / μL; about 1000 cells / μL to 2500 cells / μL; Achieve an ANC of about 1500 cells / μL to 2500 cells / μL; about 2000 cells / μL to 2500 cells / μL; about 500 cells / μL to 2000 cells / μL; about 1000 cells / μL to 2000 cells / μL; about 1500 cells / μL to 2000 cells / μL; about 500 cells / μL to 1500 cells / μL; about 1000 cells / μL to 1500 cells / μL; or about 500 cells / μL to 1000 cells / μL.
[0086] In some embodiments, the method achieves an ALC of about 1000 cells / μL to 3000 cells / μL; about 1500 cells / μL to 3000 cells / μL; about 2000 cells / μL to 3000 cells / μL; about 2500 cells / μL to 3000 cells / μL; 1000 cells / μL to 2500 cells / μL; about 1500 cells / μL to 2500 cells / μL; about 2000 cells / μL to 2500 cells / μL; 1000 cells / μL to 2000 cells / μL; about 1500 cells / μL to 2000 cells / μL; or about 1500 cells / μL to 2000 cells / μL.
[0087] In some embodiments, the method achieves an ANC of about 500 cells / μL to 3,000 cells / μL and an absolute leukocyte count ALC of about 1,000 to 3,000 cells / μL, or any combination of the aforementioned ranges.
[0088] In some embodiments, the method described herein achieves an ANC of at least 1500 cells / μL, or at least a twofold increase in ANC when the patient has an ANC level of 500 cells / μL or less prior to treatment.
[0089] In some embodiments, the method described herein achieves an ANC of at least 1500 cells / μL in at least 60% of the evaluations, or achieves at least a twofold increase in ANC when the patient has an ANC level of 500 cells / μL or less prior to treatment.
[0090] In some embodiments, the method described herein achieves an ANC of at least 1500 cells / μL in at least 65% of the evaluations, or achieves at least a twofold increase in ANC when the patient has an ANC level of 500 cells / μL or less prior to treatment.
[0091] In some embodiments, the method described herein achieves an ANC of at least 1500 cells / μL in at least 70% of the evaluations, or achieves at least a twofold increase in ANC when the patient has an ANC level of 500 cells / μL or less prior to treatment.
[0092] In some embodiments, the method described herein achieves an ANC of at least 1500 cells / μL in at least 80% of the evaluations, or achieves at least a twofold increase in ANC when the patient has an ANC level of 500 cells / μL or less prior to treatment.
[0093] In some embodiments, the method described herein achieves an ANC of at least 1500 cells / μL, or at least a twofold increase in ANC when the patient has an ANC level of 500 cells / μL or less prior to treatment, in at least 50%, at least 55%, at least 60%, at least 65%, at least 75%, at least 85%, at least 90%, or at least 95% of the evaluation, or in about 50% to about 75%, about 50% to about 65%, about 60% to about 80%, or about 70% to about 90% of the evaluation.
[0094] In some embodiments, the method described herein achieves an ANC of at least 2000 cells / μL, or at least a 2.5-fold increase in ANC when the patient has an ANC level of 500 cells / μL or less prior to treatment.
[0095] In some embodiments, the method described herein achieves an ANC of at least 2000 cells / μL, or at least 2.5 times the increase in ANC when the patient has an ANC level of 500 cells / μL or less prior to treatment, in at least 50%, at least 55%, at least 60%, at least 65%, at least 75%, at least 85%, at least 90%, or at least 95% of the evaluation, or in about 50% to about 75%, about 50% to about 65%, about 60% to about 80%, or about 70% to about 90% of the evaluation.
[0096] In some embodiments, the method described herein achieves an ANC of at least 2500 cells / μL, or at least a three-fold increase in ANC when the patient has an ANC level of 500 cells / μL or less prior to treatment.
[0097] In some embodiments, the method described herein achieves an ANC of at least 2500 cells / μL, or at least a threefold increase in ANC when the patient has an ANC level of 500 cells / μL or less prior to treatment, in at least 50%, at least 55%, at least 60%, at least 65%, at least 75%, at least 85%, at least 90%, or at least 95% of the evaluation, or in about 50% to about 75%, about 50% to about 65%, about 60% to about 80%, or about 70% to about 90% of the evaluation.
[0098] As described above, patients being treated for neutropenia may receive treatment using G-CSF, GM-CSF, or either variant.
[0099] The method described herein may increase or decrease the absolute neutrophil count (ANC) and / or increase the absolute lymphocyte count (ALC) in a patient, for example, in the patient's blood. In some embodiments, the patient's ANC and / or ALC is increased or decreased by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or at least 50% of the baseline value prior to treatment.
[0100] In some embodiments, the method described herein increases the absolute neutrophil count (ANC) to a level of 500 / μL or higher and / or increases the absolute lymphocyte count (ALC) to a level of 1000 / μL or higher.
[0101] In some embodiments, the patient originally has an ANC of less than 600 / μL and / or an ALC of less than 1000 / μL prior to treatment. In some embodiments, the patient originally has an ANC of less than 500 / μL and / or an ALC of less than 650 / μL prior to treatment.
[0102] In some embodiments, the method described herein increases the ANC level at least about 500 / μL, at least about 600 / μL, at least about 700 / μL, at least about 800 / μL, at least about 900 / μL, at least about 1000 / μL, at least about 1,100 / μL, at least about 1,200 / μL, at least about 1,300 / μL, at least about 1,400 / μL, at least about 1,500 / μL, or to the level of a human having a normally functioning immune system in at least 85% of the evaluation.
[0103] In some embodiments, the method described herein increases ALC to at least about 1000 / μL, about 1200 / μL, or about 1500 / μL or to the level of a human having a normally functioning immune system in at least 85% of the evaluation.
[0104] In some embodiments, the method described herein results in a reduction in the frequency of infection in a patient, e.g., a reduction of at least 10%, at least 25%, or at least 50% of infection. In some embodiments, the method reduces the frequency of respiratory infections. In some embodiments, the method described herein results in a reduction in the severity and / or duration of infection.
[0105] In some embodiments, the method described herein results in an increase in the levels of total circulating WBCs, neutrophils, and / or lymphocytes. In some embodiments, the cell count of WBCs, neutrophils, and / or lymphocytes increases to about 1.4x of the baseline. In some embodiments, the cell count of WBCs, neutrophils, and / or lymphocytes increases to about 1.6x of the baseline, 1.8x of the baseline, or 2.0x of the baseline. In some embodiments, the cell count of WBCs, neutrophils, and / or lymphocytes increases to about 2.9x of the baseline. In some embodiments, the cell count of lymphocytes increases to about 2.9x of the baseline. In some embodiments, the cell count of neutrophils increases to about 2.7x of the baseline and lymphocytes increase to about 1.9x of the baseline.
[0106] In some embodiments, the method provides an increased maximum plasma concentration (Cmax) and / or area under the curve (AUC) of mavorixafor compared to mavorixafor administered to a non-fasting patient. In some embodiments, the non-fasting patient fasted for less than 7 hours, e.g., 6, 5, 4, 3, or less than 2 hours. In some embodiments, the non-fasting patient fasted for 1 hour or less.
[0107] In some embodiments, the method provides a maximum plasma concentration (Cmax) of at least 3,700 μg / mL of maborixaphor and / or an area under the curve over 24 hours (AUC0-24) of at least 16,000 μg / mL.
[0108] In some embodiments, the method provides a maximum plasma concentration (Cmax) of at least 4,000 μg / mL of maborixaphor and / or an area under the curve (AUC0-24) over 24 hours of at least 17,000 μg / mL.
[0109] In some embodiments, the method provides a maximum plasma concentration (Cmax) of at least 4200 μg / mL of maborixaphor and / or an area under the curve (AUC0-24) over 24 hours of at least 18,000 μg / mL.
[0110] In some embodiments, the method provides a maximum plasma concentration (Cmax) of about 3,700 to about 7,500 μg / mL of maborixaphor and / or an area under the curve (AUC0-24) over 24 hours of about 16,000 to 25,000 μg / mL.
[0111] In some embodiments, the method obtains an average maximum plasma concentration (Cmax) of about 3,700 to about 7,500 μg / mL of maborixaphor and / or an average area under the curve (AUC) over 24 hours of about 16,000 to 25,000 μg / mL in groups of two or more patients. 0-24 It provides ).
[0112] In some embodiments, the method has an average maximum plasma concentration of mavorixafor (C) in a group of two or more patients that is about 15% to 30% greater than that in a comparable group of two or more patients administered mavorixafor in a non-fasting state. max ) providing; and / or the method provides an average area under the curve (AUC) over 24 hours that is about 15% to 30% larger than that in a comparable group of two or more patients administered mavorixafor in a non-fasting state. 0-24 ) provides. In some embodiments, the method provides an average maximum plasma concentration of mavorixafor (C) in a group of two or more patients that is about 20% greater than that in a comparable group of two or more patients administered mavorixafor while non-fasting. max ) providing; and / or the method provides an average area under the curve (AUC) over 24 hours that is about 20% larger than that in a comparable group of two or more patients administered maborixafor in a non-fasting state. 0-24 ) provides. In some embodiments, the method provides an average maximum plasma concentration of mavorixafor (C) in a group of two or more patients that is about 30% greater than that in a comparable group of two or more patients administered mavorixafor while non-fasting. max ) providing; and / or the method provides an average area under the curve (AUC) over 24 hours that is about 30% larger than that in a comparable group of two or more patients administered mavorixafor in a non-fasting state. 0-24 ) provides. In some embodiments, the method provides an average maximum plasma concentration of mavorixafor (C) in a group of two or more patients that is about 30% to about 50% greater than that in a comparable group of two or more patients administered mavorixafor while non-fasting. max) providing; and / or the method provides an average area under the curve (AUC) over 24 hours that is about 30% to about 50% larger than that in a comparable group of two or more patients administered maborixafor in a non-fasting state. 0-24 ) provides. In some embodiments, the method provides an average maximum plasma concentration of mavorixafor (C) in a group of two or more patients that is at least 30% greater than that in a comparable group of two or more patients administered mavorixafor while non-fasting. max ) providing; and / or the method provides an average area under the curve (AUC) over 24 hours that is at least 30% larger than that in a comparable group of two or more patients administered mavorixafor in a non-fasting state. 0-24 It provides ). In some embodiments, non-fasting patients fasted for less than 7 hours, e.g., 6, 5, 4, 3, or less than 2 hours. In some embodiments, non-fasting patients fasted for 1 hour or less.
[0113] Because patients with neutropenia may have varying levels of endogenous G-CSF, administering additional G-CSF may be ineffective or even dangerous (e.g., in patients with high levels of endogenous G-CSF). The methods described herein may be modified accordingly to take into account the patient's endogenous G-CSF. In some embodiments of any of the methods described herein, the patient is about 10 2 The patient has an endogenous G-CSF concentration of pg / mL or less. In some embodiments, the patient is about 10 2 pg / mL to 10 3 The patient has an endogenous G-CSF concentration of pg / mL. In some embodiments, the patient has about 10 2 pg / mL to 10 4 The patient has an endogenous G-CSF concentration of pg / mL. In some embodiments, the patient has about 10 2 pg / mL to 105 The patient has an endogenous G-CSF concentration of pg / mL. In some embodiments, the patient has about 10 3 pg / mL to 10 4 The patient has an endogenous G-CSF concentration of pg / mL. In some embodiments, the patient has about 10 3 pg / mL to 10 5 The patient has an endogenous G-CSF concentration of pg / mL. In some embodiments, the patient has about 10 4 pg / mL to 10 5 The patient has an endogenous G-CSF concentration of pg / mL. In some embodiments, the patient has about 10 5 The patient has an endogenous G-CSF concentration of pg / mL or higher. In some embodiments, the patient has an endogenous G-CSF concentration of about 10 pg / mL or lower, about 10 2 pg / mL, about 10 3 pg / mL, about 10 4 pg / mL, about 10 5 pg / mL, about 10 6 It has an endogenous G-CSF concentration of pg / mL or higher.
[0114] In some embodiments of the method described herein, the patient is administered a first dose of G-CSF, GM-CSF, or any one variant once a day.
[0115] In some embodiments, the patient receives a first dose of G-CSF, GM-CSF, or any one variant at a rate of 0.1 mcg / kg, 0.2 mcg / kg, 0.2 mcg / kg, 0.3 mcg / kg, 0.4 mcg / kg, 0.5 mcg / kg, 0.6 mcg / kg, 0.7 mcg / kg, 0.8 mcg / kg, 0.9 mcg / kg, 1.0 mcg / kg, 1.1 mcg / kg, 1.2 mcg / kg, 1.3 mcg / kg, 1.4 mcg / kg, 1.5 mcg / kg, 1.6 mcg / kg, 1.7 mcg / kg, 1.8 mcg / kg, 1.9 mcg / kg, 2.0 mcg / kg, 2.1 mcg / kg, 2.2mcg / kg, 2.3mcg / kg, 2.4mcg / kg, 2.5mcg / kg, 2.6mcg / kg, 2.7mcg / kg, 2.8mcg / kg, 2.9mcg / kg, 3.0mcg / kg, 3.1mcg / kg, 3.2mcg / kg, 3.3mcg / kg, 3.4mcg / kg, 3.5mcg / kg, 3.6mcg / kg, 3.7mcg / kg, 3.8mcg / kg, 3.9mcg / kg, 4.0mcg / kg, 4.1mcg / kg, 4.2mcg / kg, 4.3mcg / kg, 4.4mcg / kg, 4.5mcg / kg, 4.6 mcg / kg, 4.7 mcg / kg, 4.8 mcg / kg, 4.9 mcg / kg, 5.0 mcg / kg, 5.1 mcg / kg, 5.2 mcg / kg, 5.3 mcg / kg, 5.4 mcg / kg, 5.5 mcg / kg, 5.6 mcg / kg, 5.7 mcg / kg, 5.8 mcg / kg, 5.9 mcg / kg, or 6.0 mcg / kg is being administered once or twice a day, every other day, every 3 days, every week, every 2 weeks, every month, or otherwise as prescribed by the treating physician.
[0116] CXCR4 inhibitors and G-CSF combination used chronic Neutropenia therapy method
[0117] Granulocyte colony-stimulating factor is currently the standard treatment for severe chronic neutropenia (SCN). In fact, it is common practice to administer G-CSF daily (or several times a week) to patients diagnosed with chronic neutropenia, particularly those with severe neutropenia with an ANC < 500 cells / μL, to increase ANC and reduce the risk of infection. The efficacy of G-CSF for this indication has been demonstrated by placebo-controlled clinical trials that have proven the safety and efficacy of G-CSF in reducing the risk of infection in patients with SCN of various etiologies (Dale et al. (1993) Blood. 81:2496-502).
[0118] Numerous literature reports indicate that G-CSF alone was not effective in reducing mortality in patients with pneumonia (Cheng et al. (2004) Cochrane Database of Systematic Reviews, CD004400); and suggest that long-term G-CSF therapy may indicate an increased risk of conversion to MDS / AML or an increased risk of death due to sepsis (Rosenberg et al. (2006) Blood, 107:4628-4635).
[0119] G-CSF has multiple variants, including lenograstim (Granocyte®), filgrastim (Neupogen®, Zarzio®, Nivestim®, Accofil®), sustained-release (pegylated) filgrastim (pegfilgrastim, Neulasta®, Pelmeg®, Ziextenco®), and ripegfilgrastim (Lonquex®). GM-CSF (sargramoustim, Leukine ® ) is a distinct hematopoietic cytokine approved for use in various therapeutic contexts to shorten neutrophil and / or myeloid recovery time.
[0120] For the treatment of severe chronic neutropenia, Neupogen ®Filgrastim or G-CSF is indicated for a starting dose of 6 mcg / kg subcutaneously twice daily (congenital neutropenia); or 5 mcg / kg subcutaneously once daily (idiopathic or cyclic neutropenia). Additionally, chronic daily administration following the starting dose is indicated to maintain clinical benefit. The chronic daily doses for the above indications are 6 mcg / kg (congenital neutropenia); 2.1 mcg / kg (cyclic neutropenia); and 1.2 mcg / kg (idiopathic neutropenia). Neulasta ® (Pegfilgrastim or pegylated G-CSF) is not currently approved for the treatment of severe chronic neutropenia in patients other than those receiving myelosuppressive chemotherapy or radiation. It is available as a 6 mg / 0.6 mL single-dose pre-filled syringe and may be administered once per chemotherapy cycle, or twice at one-week intervals of 6 mg in subjects exposed to radiation levels exceeding 2 Gray (Gy). Neulasta ® It may also be used with an "on-body injector" packaged with a pre-filled syringe or an OBI, and Neulasta over approximately 45 minutes, starting about 27 hours after the OBI is applied to the subject's skin. ® Administer the dose.
[0121] Although the doses presented below are the FDA-approved doses for monotherapy, in certain embodiments, the present invention involves the use of a lower starting dose of filgrastim. In certain embodiments, the starting dose of filgrastim may be lower than the starting dose presented below by at least 10%, 15%, 20%, 25%, 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the dose presented above.
[0122] Bone pain experienced with G-CSF administration has generally been treated with acetaminophen and nonsteroidal anti-inflammatory drugs as first-line therapy, and antihistamines such as loratadine (10 mg oral); or a combination of famotidine and loratadine; opioids; and reduction of G-CSF are considered as second-line therapy (Lambertini et al. (2014) Crit. Rev. Oncol. Hematol. 89:112-128).
[0123] Without wishing to be bound by theory, the effect of G-CSF on neutrophil release from bone marrow is believed to be partially mediated by interfering with CXCL12 availability at the CXCR4 receptor level, while having minimal effect on other hematopoietic cell types.
[0124] Granulocyte colony-stimulating factor therapy induces a decrease in CXCL12 expression in the bone marrow (Semerad et al. (2002) Immunity. 17:413-23; Levesque et al. (2003) J Clin Invest. 111:187-96), and G-CSF results in a decrease in the surface expression of CXCR4 in neutrophils (Kim et al. (2006) Blood. 108:812-20). Indeed, in the absence of CXCR4 signaling, G-CSF does not stimulate neutrophil release from the bone marrow (Eash et al. (2009) Blood. 113:4711-19).
[0125] Without wishing to be bound by any specific theory, it is believed that certain patient populations with neutropenia can be effectively treated with a combination of certain CXCR4 inhibitors, such as maborixafor, and G-CSF or variants thereof; or with CXCR4 inhibitors, such as maborixafor, alone. Furthermore, it is believed that such treatment results in a significant increase in the patients' baseline ANC. In addition, subjects with neutropenia (or severe neutropenia) currently being treated with G-CSF, including subjects experiencing bone pain or other serious adverse reactions with G-CSF administration, may be treated with CXCR4 inhibitors such as maborixafor, and treatment with CXCR4 inhibitors is believed to reduce the dose and / or frequency of G-CSF treatment or even eliminate the need for G-CSF treatment while maintaining the ANC above a minimum threshold (e.g., at least 500 / μL ANC) to prevent infection and other manifestations of neutropenia (e.g., oral ulcers).
[0126] Similarly, without wishing to be bound by any specific theory, the inventors likewise believe that certain patients with neutropenia (with or without concomitant lymphopenia) can be effectively treated using a combination of a specific CXCR4 inhibitor, such as maborixafor, and G-CSF or a variant thereof; or a CXCR4 inhibitor, such as maborixafor, alone. Furthermore, this treatment is believed to result in a significant increase in the patient's baseline ANC while maintaining an acceptable level of absolute lymphocyte count (ALC).
[0127] For example, administration of a CXCR4 inhibitor (e.g., mavorixafor) allows for adjustment of the dose or frequency of administration of G-CSF, GM-CSF, or either variant during treatment. In some embodiments, administration of a CXCR4 inhibitor allows for reduction or discontinuation of G-CSF in at least some patients. In some cases, this reduces the risk of G-CSF-related malignancies and myelofibrosis while maintaining protection against infection, and reduces G-CSF-related bone pain. In some cases, adjusting the dose or frequency of administration of G-CSF may prevent or improve the degree and / or duration and / or occurrence of bone pain, myalgia, splenomegaly, thrombocytopenia, interstitial pneumonitis, MDS (myelodysplastic syndrome), AML, fibrosis, periodontitis, fatigue, or any combination of the foregoing conditions.
[0128] Accordingly, in one aspect, the present disclosure provides a method for treating neutropenia, the method comprising the steps of: administering an effective amount of a starting dose of a CXCR4 inhibitor and a G-CSF, GM-CSF, or any one variant to a patient during a first treatment period; and adjusting the starting dose of the G-CSF, GM-CSF, or any one variant to a second dose of the G-CSF, GM-CSF, or any one variant during a second treatment period, wherein the patient has fasted from all food and beverages except water for at least 7 hours (e.g., at least 10 hours, e.g., about 10 hours) prior to administration of the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof and has continued to fast for at least 30 minutes after administration; and the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof is administered once daily at a dose of about 100 mg to about 800 mg.
[0129] In some embodiments, the CXCR4 inhibitor or its pharmaceutically acceptable salt is mavorixapor or its pharmaceutically acceptable salt. It should be understood that in any of the methods described herein, the CXCR4 inhibitor or its pharmaceutically acceptable salt may be a CXCR4 inhibitor other than mavorixapor or its pharmaceutically acceptable salt.
[0130] In some embodiments, the first treatment period and the second treatment period do not overlap.
[0131] Any of the methods described herein may be useful for treating congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia. In some embodiments, neutropenia is congenital neutropenia. In some embodiments, neutropenia is cyclic neutropenia. In some embodiments, neutropenia is idiopathic neutropenia.
[0132] Likewise, any of the methods described herein may be useful for patients with CXCR4 mutations. In some embodiments, the patient has WHIM, ELANE, HAX1, G6PC3, GSD1b, GATA2, WAS, or SBDS mutations.
[0133] As described above, patients initiating treatment with G-CSF and CXCR4 inhibitors may experience adverse effects associated with such treatment. Accordingly, in some embodiments of the method described herein, the patient has an infection, oral ulcer, gingivitis, bone pain, myalgia, splenomegaly, interstitial pneumonia, fibrosis, periodontitis, fatigue, bone marrow failure, pancytopenia (decrease in leukocytes and / or erythrocytes and / or platelets), panleukopenia (decrease in lymphocytes such as neutrophils and / or monocytes and / or B-cells, T-cells and / or NK cells), or any combination of the above.
[0134] Therefore, in patients receiving an effective amount of CXCR4 inhibitor and an initial dose of G-CSF during the first treatment period, the initial dose of G-CSF may be adjusted to a second dose of G-CSF to reduce side effects including those mentioned above.
[0135] In some embodiments, the second dose of G-CSF, GM-CSF, or either variant is reduced by about 1% to 100% compared to the starting dose of G-CSF, GM-CSF, or either variant. In some embodiments, the second dose is reduced by about 25-75% compared to the starting dose. In some embodiments, the second dose is reduced by about 25-50% or 50-75% compared to the starting dose. In some embodiments, the second capacity is reduced by about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99% compared to the starting capacity.
[0136] Likewise, it may be useful to increase the dose of G-CSF after the first treatment period. In some embodiments, a second dose of G-CSF, GM-CSF, or either variant is increased by about 1% to 500% or more compared to the starting dose of G-CSF, GM-CSF, or either variant. In some embodiments, the second dose is increased by about 25-75% compared to the starting dose. In some embodiments, the second dose is increased by about 25-50%, 25-100%, 50-75%, or 50-100% compared to the starting dose. In some embodiments, the second dose is increased by about 75-100%, 100-200%, 200-300%, 300-400%, or 400-500%. In some embodiments, the second dose is increased by about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 200%, about 300%, about 400%, or about 500% or more compared to the starting dose. The starting dose of the CXCR4 inhibitor and the starting dose of G-CSF, GM-CSF, or any one of the variants are all further described below.
[0137] In some embodiments of the method described herein, the first treatment period may be about 1 week to about 12 months or longer. In some embodiments, the first treatment period is about 1 to 12 months. In some embodiments, the first treatment period is approximately 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-12, 2-11, 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-12, 3-11, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-12, 4-11, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-12, 5-11, 5-10, 5-9, 5-8, 5-7, 5-6, It has a period of 6-12, 6-11, 6-10, 6-9, 6-8, 6-7, 7-12, 7-11, 7-10, 7-9, 7-8, 8-12, 8-11, 8-10, 8-9, 9-12, 9-11, 9-10, 10-12, 10-11, or 11-12 months. In some embodiments, the first treatment period has a period of about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12 months or longer.
[0138] Because adjusting the starting dose to a second dose of G-CSF, GM-CSF, or either variant may not result in the desired outcome (e.g., elimination of side effects, improvement of ANC or ALC), further adjustments may be made. For example, the second dose of G-CSF, GM-CSF, or either variant during the second treatment period is further reduced or increased in subsequent treatment periods as needed. In some embodiments, the second dose is further reduced or increased to reach a third dose during the third treatment period. In some embodiments, the third dose is further reduced or increased to reach a fourth dose during the fourth treatment period. In some embodiments, the fourth dose is further reduced or increased to reach a fifth dose during the fifth treatment period. The method described herein is not limited by the number of subsequent doses and corresponding treatment periods.
[0139] In some embodiments, subsequent dose adjustments (e.g., third, fourth, fifth, sixth, seventh, or thereafter) are the same as described above for the second dose of G-CSF, GM-CSF, or any one variant. In some embodiments, subsequent treatment periods (e.g., second, third, fourth, fifth, sixth, seventh, or thereafter) are the same as described above for the first treatment period.
[0140] In some embodiments of the method described herein, the starting capacity is adjusted by a specific rate (e.g., increased or decreased). For example, in some embodiments, the starting capacity is reduced by about 10-100% per month. In some embodiments, the starting capacity is approximately 10-90%, 10-80%, 10-70%, 10-60%, 10-50%, 10-40%, 10-30%, 10-20%, 20-100%, 20-90%, 20-80%, 20-70%, 20-60%, 20-50%, 20-40%, 20-30%, 30-100%, 30-90%, 30-80%, 30-70%, 30-60%, 30-50%, 30-40%, 40-100%, 40-90%, 40-80%, 40-70%, 40-60%, 40-50%, It is reduced by 50-100%, 50-90%, 50-80%, 50-70%, 50-60%, 60-100%, 60-90%, 60-80%, 60-70%, 70-100%, 70-90%, 70-80%, 80-100%, 80-90%, or 80-100%. In some embodiments, the starting capacity is reduced by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% per month. In some embodiments, the starting capacity is increased by any of these amounts.
[0141] In some embodiments, the starting capacity is adjusted on a weekly or yearly basis according to any of the monthly amounts provided above. It should also be understood that any subsequent capacity (e.g., the 2nd, 3rd, 4th, 5th, 6th, 7th, or thereafter) may be adjusted on a monthly, weekly, or yearly basis by any of the monthly amounts provided above (e.g., may be increased or decreased).
[0142] In some embodiments of the method described herein, administration of G-CSF, GM-CSF, or any one variant is terminated. In some embodiments, administration of G-CSF, GM-CSF, or any one variant is discontinued after the first, second, third, fourth, fifth, sixth, seventh (or thereafter) treatment period. In some embodiments, administration is discontinued after the second treatment period.
[0143] In addition to adjusting the amount of G-CSF, GM-CSF, or either variant, it may be useful to adjust the frequency of administration instead or additionally. In some embodiments of the method described herein, administration of G-CSF, GM-CSF, or either variant is performed daily. In some embodiments, the frequency of administration is lower than daily administration during a second and / or subsequent treatment period. In some embodiments, the frequency of administration is reduced to every other day, once a week, once a month, once every other month, once every six months, once a year, or any frequency included in the range thereof.
[0144] It should also be understood that the frequency of administration may be increased by any amount of the amounts listed above.
[0145] It should be understood that the administration of G-CSF, GM-CSF, or any one of its variants may be discontinued at any time as part of any of the methods described herein. For example, in some embodiments, administration is discontinued between about 1 and 12 months after the start of treatment. In some embodiments, administration of G-CSF, GM-CSF, or either variant is approximately 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-12, 2-11, 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-12, 3-11, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-12, 4-11, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-12, 5-11, 5-10, 5-9, It is discontinued between 5-8, 5-7, 5-6, 6-12, 6-11, 6-10, 6-9, 6-8, 6-7, 7-12, 7-11, 7-10, 7-9, 7-8, 8-12, 8-11, 8-10, 8-9, 9-12, 9-11, 9-10, 10-12, 10-11, or 11-12 months. In some embodiments, administration is discontinued after about 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months or more after the start of treatment.
[0146] It may also be beneficial to start G-CSF administration while the patient is already being treated with a CXCR4 inhibitor.
[0147] Accordingly, in another aspect, the present disclosure provides a method for treating neutropenia in a patient requiring it, the method comprising the steps of administering an effective amount of a CXCR4 inhibitor to the patient during a first treatment period and administering a starting dose of G-CSF, GM-CSF, or any one variant to the patient during a second treatment period, wherein the patient fasts from all food and beverages except water for at least 7 hours (e.g., at least 10 hours, e.g., about 10 hours) prior to administration of the CXCR4 inhibitor or its pharmaceutically acceptable salt and continues to fast for at least 30 minutes after administration; and the CXCR4 inhibitor or its pharmaceutically acceptable salt is administered once daily at a dose of about 100 mg to about 800 mg.
[0148] In some embodiments, the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof is mavorixapor or a pharmaceutically acceptable salt thereof. It should be understood that in any of the methods described herein, the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof may be a CXCR4 inhibitor other than mavorixapor or a pharmaceutically acceptable salt thereof. The CXCR4 inhibitor includes those described herein.
[0149] It may also be beneficial to treat patients who are already being treated with G-CSF, GM-CSF, or either variant with a CXCR4 inhibitor.
[0150] Accordingly, in another aspect, the present disclosure provides a method for treating neutropenia, the method comprising the step of administering an effective amount of a CXCR4 inhibitor or a pharmaceutically acceptable salt thereof to a patient being treated with G-CSF, GM-CSF or any one variant, wherein the dose and / or frequency of administration of the G-CSF, GM-CSF or any one variant required for treatment is reduced after the patient has been administered the CXCR4 inhibitor for a certain period.
[0151] In some embodiments, the dose and / or frequency of administration of G-CSF, GM-CSF, or either variant required for treatment is reduced after the patient has received a CXCR4 inhibitor for at least one day. In some embodiments, the amount and / or frequency of administration of G-CSF, GM-CSF, or either variant required for treatment is reduced after the patient has received a CXCR4 inhibitor for at least one day, at least one week, at least one month, at least two months, at least three months, at least four months, at least five months, at least six months, at least seven months, at least eight months, at least nine months, at least ten months, at least eleven months, at least twelve months, or longer. In some embodiments, the patient has received CXCR4 treatment for about one to four months, about one to three months, about one to two months, about two to four months, about two to three months, or about three to four months.
[0152] In another aspect, the present disclosure provides a method for correcting an imbalance in the immune cell population of a subject, the method comprising the step of administering an effective amount of a CXCR4 inhibitor to a subject, wherein the patient has fasted from all food and beverages except water for at least 7 hours (e.g., at least 7 hours, e.g., about 10 hours) prior to administration of the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof and has continued to fast for at least 30 minutes after administration; and the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof is administered once daily at a dose of about 100 mg to about 800 mg.
[0153] In some embodiments, the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof is mavorixapor or a pharmaceutically acceptable salt thereof. It should be understood that in any of the methods described herein, the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof may be a CXCR4 inhibitor other than mavorixapor or a pharmaceutically acceptable salt thereof. The CXCR4 inhibitor includes those described herein.
[0154] In some embodiments, the present disclosure provides a method for correcting an imbalance in a patient's absolute neutrophil count (ANC) and / or absolute leukocyte count (ALC), the method comprising the step of administering an effective amount of a CXCR4 inhibitor to a patient, wherein the patient has fasted from all food and beverages except water for at least 7 hours (e.g., at least 10 hours, e.g., about 10 hours) prior to administration of the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof and has continued to fast for at least 30 minutes after administration; and the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof is administered once daily in a dose of about 100 mg to about 800 mg.
[0155] In some embodiments, the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof is mavorixapor or a pharmaceutically acceptable salt thereof. It should be understood that in any of the methods described herein, the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof may be a CXCR4 inhibitor other than mavorixapor or a pharmaceutically acceptable salt thereof. The CXCR4 inhibitor includes those described herein.
[0156] In some embodiments of a method for correcting an imbalance in the immune cell population of a subject, the patient is administered G-CSF, GM-CSF, or either variant. In some embodiments, the patient is administered a first dose of G-CSF, GM-CSF, or either variant at the frequency disclosed herein. For example, in some embodiments, the patient is administered the first dose once daily. In some embodiments, the patient is administered subsequent doses (e.g., first, second, third, or more).
[0157] In some embodiments, the subject has a chronic immune cell imbalance. In some embodiments, the subject has an acute immune cell imbalance. In some embodiments, the immune cell imbalance is associated with a congenital primary immunodeficiency disease (PID). In some embodiments, the immune cell imbalance is associated with a disease state. In some embodiments, the disease state is cancer. In some embodiments, the cancer is renal cell carcinoma, clear cell renal cell carcinoma, papillary renal cancer, melanoma, pancreatic cancer, ovarian cancer, non-small cell lung cancer, or Waldenstrom's macroglobulinemia (WM). In some embodiments, the cancer is leukemia or lymphoma. In some embodiments, PID is WHIM syndrome, chronic neutropenia, or severe chronic neutropenia (SCN).
[0158] The cells of the immune system can be classified into lymphocytes (T-cells, B-cells, and NK cells), neutrophils, and monocytes / macrophages. These are all types of white blood cells. The major proteins of the immune system are primarily signaling proteins (commonly called cytokines), antibodies, and complement proteins.
[0159] In some embodiments, the method provided by the present invention corrects a B-cell imbalance in a subject. B-cells (sometimes called B-lymphocytes) are specialized cells of the immune system whose primary function is to produce antibodies (also called immunoglobulins or gamma-globulins). B-cells develop from hematopoietic stem cells in the bone marrow. As part of maturation in the bone marrow, B-cells are trained or educated not to produce antibodies against healthy tissues. Upon maturation, B-cells can be found in the bone marrow, lymph nodes, spleen, parts of the intestines, and the bloodstream.
[0160] In some embodiments, the method provided by the present invention corrects T-cell imbalance in a subject. T-cells (sometimes called T-lymphocytes and commonly referred to as CD3 cells in laboratory reports) directly attack virus-infected cells and also act as regulators of the immune system. T-cells develop from hematopoietic stem cells in the bone marrow but complete their development in the thymus. The thymus is a specialized organ of the immune system located in the chest. Within the thymus, immature lymphocytes develop into mature T-cells, and T-cells that are likely to attack normal tissues are eliminated. The thymus is essential to this process; without a thymus in the fetus, T-cells cannot develop. Mature T-cells leave the thymus and are distributed to other organs of the immune system, such as the spleen, lymph nodes, bone marrow, and blood. Each T-cell reacts with a specific antigen, just as each antibody molecule reacts with a specific antigen.
[0161] T cells differ in their ability to recognize antigens and possess diverse functions. There are "killer" or cytotoxic T cells (commonly labeled as CD8 T cells on laboratory reports), helper T cells (commonly labeled as CD4 T cells on laboratory reports), and regulatory T cells. Each plays a different role in the immune system. Killer or cytotoxic T cells actually destroy infected cells. Killer T cells protect the body from certain bacteria and viruses that can survive and even multiply within the body's own cells. Killer T cells also respond to foreign tissues within the body, such as transplanted organs. Killer cells must migrate to the site of infection and bind directly to the target to ensure it is destroyed. Helper T cells assist B cells in producing antibodies and help killer T cells attack foreign substances. Regulatory T cells suppress or inactivate other T lymphocytes.
[0162] Natural killer (NK) cells are named as such because they readily kill virus-infected cells. They are called "natural killer" cells because they do not require the same thymic training that T-cells require. NK cells originate from the bone marrow and exist in relatively small numbers in the bloodstream and tissues. They are important for defense against viruses and may also be important for preventing cancer.
[0163] In some embodiments, the method provided by the present invention corrects neutrophil imbalance in a subject. Neutrophils, or polymorphonuclear leukocytes (polys or PMNs), are the most numerous of all types of white blood cells, constituting more than half of the total. They are also called granulocytes and appear as part of a complete blood count (CBC) that includes differentiation in laboratory reports. They are found in the bloodstream and can migrate to the site of infection within minutes. Like other cells of the immune system, these cells develop from hematopoietic stem cells in the bone marrow. Neutrophils increase in number in the bloodstream during infection and contribute significantly to the white blood cell count elevation observed in some infections. They may leave the bloodstream during the first few hours of infection and accumulate in tissues. Their primary role is to engulf and kill bacteria or fungi.
[0164] In some embodiments, the method provided by the present invention corrects a monocyte imbalance (monucopenia) in a subject. Monocytes are closely related to neutrophils and circulate in the bloodstream. They constitute 5–10 percent of white blood cells. They are also present along the walls of blood vessels in organs such as the liver and spleen. There, they capture microorganisms in the blood as they pass through. Mononucleosis is defined as a blood monocyte count (ANC) of <500 / mcL (< 0.5 × 10⁻¹⁰). 9 It decreases to / L. The risk of certain infections increases. This is diagnosed by a complete blood count including differential diagnosis. Typical treatment involves hematopoietic stem cell transplantation.
[0165] Macrophages are essential for killing fungi and certain bacteria. They survive longer than neutrophils and are particularly important for slow-growing or chronic infections. Macrophages can be influenced by T cells and often cooperate with them to kill microorganisms.
[0166] In some embodiments, the subject has an imbalance of immune cell populations selected from T-cells, B-cells, NK cells, neutrophils, and monocytes. In some embodiments, the subject has leukopenia, neutropenia, or mononucleopenia. In some embodiments, the subject exhibits a low total white blood cell (WBC) count.
[0167] In another aspect, the present disclosure provides a method for reducing the dose or frequency of administration of G-CSF, GM-CSF, or any one variant required to treat neutropenia in a patient, the method comprising the steps of: determining the patient's initial absolute neutrophil count (ANC); and reducing the dose or frequency of administration of G-CSF, GM-CSF, or any one variant to a second dose of G-CSF, GM-CSF, or any one variant sufficient to lower the patient's initial ANC, wherein the patient has fasted from all food and beverages except water for at least 7 hours (e.g., at least 10 hours, e.g., about 10 hours) prior to administration of the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof and has continued to fast for at least 30 minutes after administration; and the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof is administered once daily at a dose of about 100 mg to about 800 mg.
[0168] In some embodiments, the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof is mavorixapor or a pharmaceutically acceptable salt thereof. It should be understood that in any of the methods described herein, the CXCR4 inhibitor or a pharmaceutically acceptable salt thereof may be a CXCR4 inhibitor other than mavorixapor or a pharmaceutically acceptable salt thereof. The CXCR4 inhibitor includes those described herein.
[0169] In some embodiments, the method further comprises the step of determining the patient's ANC after the patient has been administered a second dose for at least one week; and the step of reducing the second dose or the frequency of the second dose to a third dose, wherein the third dose or the frequency of the third dose is reduced by 50% compared to the second dose.
[0170] In some embodiments, the second dose is administered at a frequency lower than daily. In some embodiments, the second dose is administered every other day. In some embodiments, the second dose is administered once a week.
[0171] As discussed above, any of the methods described herein may improve specific side effects or symptoms associated with treatment using a CXCR4 inhibitor and / or G-CSF, GM-CSF, or any variant thereof. In some embodiments, the methods described herein result in improvement of the frequency, severity, duration, or time to the next infection of infection; the occurrence and / or disappearance of oral ulcers; the appearance and / or disappearance of gingivitis; or any combination of the foregoing. In some embodiments, the methods described herein result in improvement of the degree, duration, and / or occurrence of G-CSF-induced bone pain, myalgia, splenomegaly, thrombocytopenia, interstitial pneumonia, MDS, AML, fibrosis, periodontitis, fatigue, or any combination of the foregoing.
[0172] In some embodiments of any of the methods described herein, the patient has a CXCR4 mutation. In some embodiments, the patient has a WHIM, ELANE, HAX1, G6PC3, GSD1b, GATA2, WAS, or SBDS mutation.
[0173] In some embodiments of the method described herein, a first or starting dose of G-CSF, CM-CSF, or any one variant is increased or decreased to a second dose to achieve an ANC of at least 500 cells / μL and / or an absolute leukocyte count (ALC) of at least 1,000 / μL. In some embodiments, a first or starting dose of any method described herein is increased or decreased to achieve an ANC of about 1,000 cells / μL to 10,000 cells / μL. In some embodiments, a first or starting dose of any method described herein is about 1,000 cells / μL to 10,000 cells / μL; about 1,000 cells / μL to 9,000 cells / μL; about 1,000 cells / μL to 8,000 cells / μL; about 1,000 cells / μL to 7,000 cells / μL; About 1,000 cells / μL to 6,000 cells / μL; about 1,000 cells / μL to 5,000 cells / μL; about 1,000 cells / μL to 4,000 cells / μL; about 1,000 cells / μL to 3,000 cells / μL; about 1,000 cells / μL to 2,000 cells / μL; about 2,000 cells / μL to 10,000 cells / μL; about 2,000 cells / μL to 9,000 cells / μL; about 2,000 cells / μL to 8,000 cells / μL; about 2,000 cells / μL to 7,000 cells / μL; about 2,000 cells / μL to 6,000 cells / μL; About 2,000 cells / μL to 5,000 cells / μL; about 2,000 cells / μL to 4,000 cells / μL; about 2,000 cells / μL to 3,000 cells / μL; about 3,000 cells / μL to 10,000 cells / μL; about 3,000 cells / μL to 9,000 cells / μL; about 3,000 cells / μL to 8,000 cells / μL; about 3,000 cells / μL to 7,000 cells / μL; about 3,000 cells / μL to 6,000 cells / μL; about 3,000 cells / μL to 5,000 cells / μL; about 3,000 cells / μL to 4,000 cells / μL; About 4,000 cells / μL to 10,000 cells / μL;About 4,000 cells / μL to 9,000 cells / μL; about 4,000 cells / μL to 8,000 cells / μL; about 4,000 cells / μL to 7,000 cells / μL; about 4,000 cells / μL to 6,000 cells / μL; about 4,000 cells / μL to 5,000 cells / μL; about 5,000 cells / μL to 10,000 cells / μL; about 5,000 cells / μL to 9,000 cells / μL; about 5,000 cells / μL to 8,000 cells / μL; about 5,000 cells / μL to 7,000 cells / μL; about 5,000 cells / μL to 6,000 cells / μL; It is increased or decreased to achieve an ANC of about 6,000 cells / μL to 10,000 cells / μL; about 6,000 cells / μL to 9,000 cells / μL; about 6,000 cells / μL to 8,000 cells / μL; about 6,000 cells / μL to 7,000 cells / μL; about 7,000 cells / μL to 10,000 cells / μL; about 7,000 cells / μL to 9,000 cells / μL; about 7,000 cells / μL to 8,000 cells / μL; about 8,000 cells / μL to 10,000 cells / μL; about 8,000 cells / μL to 9,000 cells / μL; or about 9,000 cells / μL to 10,000 cells / μL. In some embodiments, the first or starting dose of any of the methods described herein is increased or decreased to achieve an ANC of about 1,000; 2,000; 3,000; 4,000; 5,000; 6,000; 7,000; 8,000; 9,000; or 10,000 cells / μL.
[0174] It should be understood that in some embodiments, any subsequent increase or decrease in capacity of the method described herein (e.g., a second, third, fourth, or more) may achieve any of the aforementioned ANC levels.
[0175] In some embodiments, the method described herein achieves at least 500 cells / μL of ANC and / or at least 1000 / μL of ALC.
[0176] In some embodiments, if a patient is receiving a first or starting dose of G-CSF, GM-CSF, or either variant and the patient's ANC is less than about 500 cells / μL, less than about 1,000 cells / μL, or less than about 1,500 cells / μL or greater, the second dose is 10%, 20%, 30%, 40%, 50% or greater than the first dose. It should be understood that any subsequent dose (e.g., at any subsequent treatment period) may be increased accordingly.
[0177] In some embodiments, if a patient is receiving a first or starting dose of G-CSF, GM-CSF, or any variant and the patient's ANC is greater than about 10,000 cells / μL, or is about 9,000 cells / μL, 8,000 cells / μL, 7,000 cells / μL, 6,000 cells / μL, 5,000 cells / μL, 4,000 cells / μL, or lower, a second dose is about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% lower than the first dose. It should be understood that any subsequent dose (e.g., at any subsequent treatment period) may be reduced accordingly.
[0178] In some embodiments, the frequency of administration of the first or starting dose of G-CSF, GM-CSF, or either variant is reduced or increased, for example, by at least 25%, 50%, 75%, or 90%. It should be understood that any subsequent dose (e.g., second, third, fourth, or more) at any subsequent treatment period may be increased or decreased accordingly. In some embodiments, the administration interval is increased (e.g., once every three days instead of once every two days).
[0179] CXCR4 inhibitor
[0180] As described herein, various CXCR4 inhibitors may be used in accordance with the present disclosure.
[0181] In some embodiments, the CXCR4 inhibitor is mavorixafor (X4P-001; AMD11070) or a pharmaceutically acceptable salt thereof. Mavorixafor is currently in clinical development in patients with cancer (renal cell carcinoma), Waldenström macroglobulinemia and warts, hypogammaglobulinemia, infection, and myeloid catechism (WHIM) syndrome. The chemical formula is as follows: C 21 H 27 N5; and the molecular weight is 349.48 amu. The chemical structure of Maborixaphor is as follows according to Chemical Formula I:
[0182]
[0183] In some embodiments, the CXCR4 inhibitor is one of the ones described in the following literature or a pharmaceutically acceptable salt thereof: WO2017223229, WO2017223239, WO2017223243, WO2019126106, WO2020 / 264292, WO2003 / 022785, WO2003 / 055876, WO2004 / 106493, WO2004 / 091518, WO2004 / 093817, WO2006 / 049764, WO2005 / 090308, WO2021 / 263203, WO2023059903, or WO2006 / 039250. Each of the foregoing literature is incorporated herein by reference in its entirety.
[0184] In some embodiments, the CXCR4 inhibitor is maborixapor,
[0185]
[0186] Or is selected from its pharmaceutically acceptable salt or composition.
[0187] In some embodiments, the CXCR4 inhibitor is plerixafor or a pharmaceutically acceptable salt thereof.
[0188] In some embodiments, the CXCR4 inhibitor is maborixapor or a pharmaceutically acceptable salt or composition thereof.
[0189] In some embodiments, the CXCR4 inhibitor is as follows:
[0190]
[0191] Or it is a pharmaceutically acceptable salt thereof.
[0192] In some embodiments, the CXCR4 inhibitor is selected from the following:
[0193]
[0194] Or it is a pharmaceutically acceptable salt thereof.
[0195] In some embodiments, the CXCR4 inhibitor is one of those listed in Table 1 below. Each document listed in Table 1 is incorporated herein by reference in its entirety.
[0196] [Table 1]
[0197] Exemplary CXCR4 inhibitor
[0198]
[0199]
[0200]
[0201]
[0202]
[0203] volume and Formulation
[0204] In some embodiments, the dose of the CXCR4 inhibitor is a well-tolerated dose that achieves a satisfactory therapeutic result without causing any severe or treatment-limiting toxicity.
[0205] With respect to the dosage of CXCR4 inhibitors (e.g., mavorixafor) used herein, the term "well tolerated" means a dose that can be administered to a patient without the patient experiencing any treatment-limiting toxicities. As used herein, "treatment-limiting toxicities (TLT)" refers to a patient Table 2 It means experiencing one or more of the toxicities:
[0206] [Table 2]
[0207] Treatment-limiting toxicity
[0208]
[0209] Classification: As defined by the National Cancer Institute [NCI] Common Terminology Standards for Adverse Reactions, Version 4.03.
[0210] abbreviation: ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; TLT = Treatment-limiting toxicity.
[0211] In some embodiments, a CXCR4 inhibitor (e.g., mavorixafor) or a pharmaceutically acceptable salt thereof may be administered orally (PO) once daily (QD). In some embodiments, the CXCR4 inhibitor is administered orally (PO) once daily (QD). In some embodiments, the CXCR4 inhibitor is administered orally (PO) twice daily (BD).
[0212] In some embodiments, the CXCR4 inhibitor described herein is maborixapor or a pharmaceutically acceptable salt thereof.
[0213] In certain embodiments, a composition comprising maborixafor, a pharmaceutically acceptable salt thereof, or maborixafor or a pharmaceutically acceptable salt thereof is administered orally (PO) once daily (QD) or twice daily (BID) in an amount of about 25 mg to about 800 mg daily. In certain embodiments, the administration composition may be provided twice daily in divided doses spaced about 12 hours apart. In other embodiments, the administration composition may be provided once daily. The terminal half-life of maborixafor has been determined to generally be about 12 to about 24 hours or about 14.5 hours. In certain embodiments, the dose of maborixafor useful in the present invention is about 25 mg to about 1200 mg daily. In another embodiment, the dosage of maborixaphor useful for the present invention may be in the range of about 25 mg to about 1000 mg per day, about 50 mg to about 800 mg per day, about 50 mg to about 600 mg per day, about 50 mg to about 500 mg per day, about 50 mg to about 400 mg per day, about 100 mg to about 800 mg per day, about 100 mg to about 600 mg per day, about 100 mg to about 500 mg per day, about 100 mg to about 400 mg per day; about 200 mg to about 800 mg per day, about 200 mg to about 600 mg per day, about 300 mg to about 600 mg per day, about 200 mg to about 500 mg per day, and about 200 mg to about 400 mg per day.
[0214] In another embodiment, the dose of maborixafor or a pharmaceutically acceptable salt thereof is in a dose range of about 100 mg to about 800 mg daily, about 200 mg to about 600 mg daily, about 300 mg to about 500 mg daily, or about 350 mg to about 450 mg daily; or about 100 mg / day; 125 mg / day; 150 mg / day; 175 mg / day; 200 mg / day; 225 mg / day; 250 mg / day; 275 mg / day; 300 mg / day; 325 mg / day; 350 mg / day; 400 mg / day; 425 mg / day; 450 mg / day; 475 mg / day; 500 mg / day; 525 mg / day; 550 mg / day; 575 mg / day; It is administered at daily doses of 600 mg / day; 625 mg / day; 650 mg / day; 675 mg / day; 700 mg / day; 725 mg / day; 750 mg / day; 775 mg / day; or 800 mg / day. In rare cases, doses of maborixafor or its pharmaceutically acceptable salts may be administered in amounts exceeding 800 mg / day, with care to minimize or avoid any adverse reactions resulting from such administration.
[0215] In some embodiments of the method described herein, the dose of G-CSF, GM-CSF, or any one variant (e.g., starting dose, first dose, second dose, third dose, fourth dose, etc.) is in the range of about 0.2 mcg / kg to 6.0 mcg / kg. In some embodiments, the volume is about 0.2 mcg / kg to 0.5 mcg / kg, 0.2 mcg / kg to 0.8 mcg / kg, 0.2 mcg / kg to 1.0 mcg / kg, 0.2 mcg / kg to 1.2 mcg / kg, 0.5 mcg / kg to 0.8 mcg / kg, 0.5 mcg / kg to 1.0 mcg / kg, 0.5 mcg / kg to 1.5 mcg / kg, 1.0 mcg / kg to 1.5 mcg / kg, 1.0 mcg / kg to 1.8 mcg / kg, 1.0 mcg / kg to 2.0 mcg / kg, 1.5 mcg / kg to 2.0 mcg / kg, 1.5 mcg / kg to 2.5mcg / kg, 2.0mcg / kg to 2.5mcg / kg, 2.0mcg / kg to 3.0mcg / kg, 2.5mcg / kg to 3.0mcg / kg, 2.5mcg / kg to 3.5mcg / kg, 3.0mcg / kg to 3.5mcg / kg, 3.0mcg / kg to 4.0mcg / kg, 3.5mcg / kg to 4.0mcg / kg, 3.5mcg / kg to 4.5mcg / kg, 4.0mcg / kg to 4.5mcg / kg, 4.0mcg / kg to 5.0mcg / kg, 4.5mcg / kg to 5.0mcg / kg, 4.5mcg / kg to The dosage is in the range of 5.5 mcg / kg, 5.0 mcg / kg to 5.5 mcg / kg, or 5.0 mcg / kg to 6.0 mcg / kg, and is administered once or twice daily, every other day, every three days, weekly, every two weeks, monthly, or otherwise as prescribed by the treating physician. Administration may be performed by intravenous (iv), subcutaneous (sc), or intramuscular (im) injection, or otherwise as prescribed by the treating physician.
[0216] In certain embodiments, the method disclosed herein may include the step of administering a composition comprising maborixafor or a pharmaceutically acceptable salt thereof, one or more diluents, disintegrants, lubricants, flow aids, and wetting agents. In some embodiments, the method disclosed includes the step of administering a composition comprising 25 mg to 1200 mg of maborixafor or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, dibasic calcium phosphate dihydrate, croscarmellose sodium, stearyl fumarate sodium, colloidal silicon dioxide, and sodium lauryl sulfate. In some embodiments, the method disclosed includes the step of administering a unit dosage form comprising a composition comprising 25 mg to 200 mg of maborixafor or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, dibasic calcium phosphate dihydrate, croscarmellose sodium, stearyl fumarate sodium, colloidal silicon dioxide, and sodium lauryl sulfate. In a specific embodiment, the disclosed method comprises the step of administering a unit dosage form comprising a composition containing maborixafor or a pharmaceutically acceptable salt thereof present in an amount of about 25 mg, about 40 mg, about 50 mg, about 80 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, about 1000 mg, about 1050 mg, about 1100 mg, about 1150 mg, or about 1200 mg. In some embodiments, the provided composition (or unit dosage form) is administered to a patient once, twice, three times, or four times a day. In some embodiments, the provided composition (or unit dosage form) is administered to a patient once or twice a day.
[0217] In some embodiments, the disclosed method comprises the step of administering a unit dosage form comprising a composition including the following:
[0218] (a) About 10-30% of maborixaphor or a pharmaceutically acceptable salt thereof based on the weight of the composition;
[0219] (b) Approximately 60-80% microcrystalline cellulose based on the weight of the composition;
[0220] (c) Approximately 5-10% of croscarmellose sodium based on the weight of the composition;
[0221] (d) About 0.5-2% of sodium stearyl fumarate based on the weight of the composition; and
[0222] (e) Approximately 0.1-1.0% of colloidal silicon dioxide based on the weight of the composition.
[0223] In some embodiments, the disclosed method comprises the step of administering a unit dosage form comprising a composition including the following:
[0224] (a) About 15% of maborixaphor or a pharmaceutically acceptable salt thereof, based on the weight of the composition;
[0225] (b) Approximately 78% microcrystalline cellulose based on the weight of the composition;
[0226] (c) Approximately 6% of croscarmellose sodium based on the weight of the composition;
[0227] (d) About 1% sodium stearyl fumarate based on the weight of the composition; and
[0228] (e) Approximately 0.2% of colloidal silicon dioxide based on the weight of the composition.
[0229] In some embodiments, the disclosed method comprises the step of administering a unit dosage form comprising a composition including the following:
[0230] (a) About 10-20% of maborixafor or a pharmaceutically acceptable salt thereof based on the weight of the composition;
[0231] (b) Approximately 25-40% microcrystalline cellulose based on the weight of the composition;
[0232] (c) Approximately 35-55% of dibasic calcium phosphate dihydrate based on the weight of the composition;
[0233] (d) Approximately 4-15% of croscarmellose sodium based on the weight of the composition;
[0234] (e) Approximately 0.3-2% sodium stearyl fumarate based on the weight of the composition;
[0235] (f) Approximately 0.1-1.5% of colloidal silicon dioxide based on the weight of the composition; and
[0236] (g) Sodium lauryl sulfate of about 0.1-1.5% based on the weight of the composition.
[0237] In some embodiments, the disclosed method comprises the step of administering a unit dosage form comprising a composition including the following:
[0238] (a) About 13% of maborixafor or a pharmaceutically acceptable salt thereof, based on the weight of the composition;
[0239] (b) Approximately 32% microcrystalline cellulose based on the weight of the composition;
[0240] (c) Approximately 44% of dibasic calcium phosphate dihydrate based on the weight of the composition;
[0241] (d) Approximately 8% of croscarmellose sodium based on the weight of the composition;
[0242] (e) Approximately 1.4% sodium stearyl fumarate based on the weight of the composition;
[0243] (f) Approximately 0.4% of colloidal silicon dioxide based on the weight of the composition; and
[0244] (g) Sodium lauryl sulfate of about 0.7% based on the weight of the composition.
[0245] In some embodiments, the disclosed method comprises the step of administering a unit dosage form comprising a composition including the following:
[0246] (a) About 35-75% of maborixaphor or a pharmaceutically acceptable salt thereof based on the weight of the composition;
[0247] (b) Approximately 5-28% microcrystalline cellulose based on the weight of the composition;
[0248] (c) Approximately 7-30% of dibasic calcium phosphate dihydrate based on the weight of the composition;
[0249] (d) Approximately 2-10% of croscarmellose sodium based on the weight of the composition;
[0250] (e) Approximately 0.3-2.5% sodium stearyl fumarate based on the weight of the composition;
[0251] (f) Approximately 0.05-1.2% of colloidal silicon dioxide based on the weight of the composition; and
[0252] (g) Sodium lauryl sulfate of about 0.2-1.2% based on the weight of the composition.
[0253] For example, since it may be desirable to administer a combination of active compounds for the purpose of treating a specific disease or condition, it is within the scope of the present invention to conveniently combine two or more pharmaceutical compositions, each containing at least one compound according to the present invention, in the form of a kit suitable for the co-administration of said compositions. Accordingly, the kit of the present invention comprises two or more separate pharmaceutical compositions, each containing at least one compound of the present invention, and means for holding said compositions separately, such as containers, divided bottles, or divided foil packets. An example of such a kit is a familiar blister pack used for packaging tablets, capsules, etc.
[0254] The kit of the present invention is particularly suitable for administering different dosage forms, e.g., oral and parenteral dosage forms, administering different compositions at different dosing intervals, or titrating different compositions against one another. To aid compliance, the kit typically includes dosing instructions and may be provided with a memory aid.
[0255] The following examples further illustrate the invention. The following manufacturing and examples are provided to enable those skilled in the art to more clearly understand and practice the invention. However, the scope of the invention is not limited by the embodiments illustrated, and these are intended only as examples of a single aspect of the invention, and functionally equivalent methods are within the scope of the invention. In fact, various variations of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying drawings. Such variations are intended to be included within the scope of the appended claims.
[0256] The contents of each document cited in the specification are incorporated herein by reference in their entirety.
[0257] Examples
[0258] Examples 1: Congenital Neutropenia and chronic Neutropenia obstacle In patients Maboric Sapor's Phase 1b / 2, Public cover, Multi-agency research
[0259] A two-part open-label, multicenter study of maborixapor (X4P-001) will be conducted on participants diagnosed with chronic neutropenia.
[0260] [Table 1]
[0261] Research Objectives and Evaluation Variables
[0262]
[0263]
[0264]
[0265] Research Design Overview : Conduct the Part 2 open-label multicenter study of Maborixafor on participants diagnosed with CN disorders defined as follows: Participants not receiving G-CSF treatment in Part 1 and Part 2: CIN is defined as a participant exhibiting an ANC ≤ 1,000 cells / μL, diagnosed at least 6 months prior to the screening visit, and not attributable to drugs or specific hereditary, infectious, inflammatory, systemic autoimmune disorders, or malignant causes as determined by clinical evaluations performed as part of routine clinical care. Participants diagnosed with autoimmune neutropenia based on anti-neutrophil antibodies are considered to have CIN and may enroll in the study; mainFor analytical purposes, participants diagnosed with autoimmune neutropenia are grouped together with those with idiopathic neutropenia. Congenital neutropenia is defined as any congenital neutropenia unrelated to genetic variation in participants exhibiting an ANC ≤ 1,000 cells / μL; cyclic neutropenia is defined as a neutropenic state in which a participant is enrolled at enrollment with an ANC ≤ 1,000 cells / μL. In Parts 1 and 2, regardless of the type of neutropenia, participants receiving G-CSF treatment must not have a lower ANC limit and an upper ANC limit ≥ 10,000 cells / μL at the screening visit. Eligible participants must be ≥ 12 years of age and weigh ≥ 15 kg.
[0266] Part 1:
[0267] Participants make two 8-hour study visits during the study: the day before maborixapor administration (baseline [Day (D)-1]) and at the time of maborixapor administration (D1). A record of maborixapor administration including the date, time, and dose of maborixapor administration is completed.
[0268] From screening onwards, participants may not change G-CSF therapy except for infection or other medically justifiable reasons. Any G-CSF treatment, including any changes after screening, must be stabilized for ≥ 14 days prior to baseline (D-1) evaluation. Any G-CSF administration must be administered at the same time of day as maborixaphor administration. Any changes to G-CSF treatment are recorded on the concomitant medications page of the electronic database.
[0269] Screening evaluationIn the discussion regarding the study design and purpose, the value of genetic screening is explained to the participants. After signing the informed consent form (ICF), blood tests (or buccal samples) using targeted NGS are performed to complete genetic screening for genetic variations of genes known to cause chronic neutropenia, unless the participant's previous records regarding their genetic status have been documented and provided to the research institution or they refuse genetic testing.
[0270] Participant eligibility is assessed during a screening visit conducted within 28 days prior to D1. The screening (D-28 to D-1) evaluation includes the following: physical examination; medical history / surgical history including infections within the past year; height and weight; vital signs (heart rate [HR], blood pressure [BP], and body temperature); ECG at time point 0; NGS genotyping analysis where applicable; blood tests (hematology, serum chemistry, and serological measurements); serum pregnancy testing for women of childbearing potential (WOCBP) (Note: Follicle-stimulating hormone (FSH) testing is performed at screening to confirm postmenopausal status in female participants who have been amenorrheic for at least 12 consecutive months); concomitant medications; AE monitoring.
[0271] Baseline evaluation includes the following:: Inclusion / exclusion criteria (G-CSF safety); physical examination based on symptoms; vital signs (HR, BP, and body temperature); blood collections to monitor ALC, AMC, ANC, and WBC levels at the following time points: 0, 60 minutes (± 5 minutes) and 2, 3, 4, 6, and 8 hours (± 15 minutes, respectively). These baseline values are averaged and referred to as "baseline" (i.e., baseline ALC); blood collections to monitor the immunophenotypic profile of lymphocyte subpopulations evaluated by fluorescence-activated cell sorting (FACS) at time points 0, 4, and 8 hours; blood safety tests (hematology, serum chemistry) and urine pregnancy test for WOCBP; concomitant medications; AE monitoring.
[0272] Maborixafor administration is performed on D1. Maborixafor is administered to all eligible participants as an oral (PO) QD in the morning for one day. The dose of maborixafor for adults is 400 mg QD. For adolescents (12 to < 18 years) weighing > 50 kg, the dose of maborixafor is 400 mg QD. For adolescents weighing ≤ 50 kg, 200 mg QD of maborixafor is administered.
[0273] Post-treatment evaluation : Participant safety is monitored throughout the study. The investigator may conduct additional blood draws to monitor participant safety. All participants receive a post-treatment safety follow-up call (remote) on 7D (+ 2D) after D1.
[0274] Part 2:
[0275] In Part 2, participants are administered Maborixafor as QD PO for 6 months. In Part 2, participants receiving chronic G-CSF as background therapy may continue individualized G-CSF administration for at least 8 weeks. After 8 weeks, investigators are advised to consider reducing the dose and / or frequency of G-CSF as long as the participant's ANC is maintained at > 500 cells / μL. For participants who discontinue the study early, an EOS / safety follow-up visit is conducted 30 days (± 14 days) after the last administration of study treatment, following an EOT visit.
[0276] Screening evaluation : In some cases, eligible Part 1 participants transition directly to the Part 2 baseline (D-3 to D-1) visit after the Day 7 (+ 2D) safety follow-up call in Part 1. If an eligible participant does not complete the Part 2 baseline visit within 6 weeks of the safety follow-up call, the participant is rescreened to confirm eligibility. After signing the ICF, the participant's eligibility (i.e., meeting all inclusion and exclusion criteria) is assessed unless the medical monitor approves an extension.
[0277] In some cases, participants start with a Part 2 screening visit without needing to enter Part 1.
[0278] Screening evaluation (within 6 weeks prior to D1) includes the following: infection assessment (Note: Infection assessment must be performed before all other procedures); history of CN treatment, history / surgical history including infection within the past year; NGS genotyping analysis if applicable; physical examination (full); height and weight; vital signs (HR, BP, and body temperature); ECG at time points 0 and 2 hours (± 15 min); blood tests (hematology, serum chemistry, and serological measurements); serum pregnancy test for WOCBP (Note: FSH testing is performed at screening to confirm postmenopausal status in female participants who have been amenorrheic for at least 12 consecutive months); concomitant medication monitoring; AE monitoring; urinalysis.
[0279] The baseline (D-3 to D-1) evaluation includes the following: : Symptomatic physical examination; vital signs (HR, BP, and body temperature); infection assessment; administration of PRO and Bone Pain and G-CSF Burden Questionnaire (Note: PRO and the questionnaires administered must be completed after infection assessment and before all other procedures. PGI-C is not assessed at baseline); blood collection to monitor ALC, AMC, ANC, and WBC levels at the following time points: 0, 60 minutes (± 5 minutes) and 2, 3, 4, 6, and 8 hours (± 15 minutes, respectively). These baseline values are averaged and subsequently referred to as "baseline" (i.e., baseline ALC); phenotypic analysis / gene expression profiling evaluated by EpiID or qPCR at time points 0, 4, and 8 hours (± 15 minutes, respectively); ophthalmic examination (all study participants) (can be performed at any time point between the screening visit and D-1); Fasting endocrine evaluation of the hypothalamic-pituitary-gonadal axis (HPG) for testicular safety testing (male participants) (Note: Male participants (12 to ≤ 50 years of age) are recommended to fast for 12 hours prior to hormone testing); G-CSF, cytokine, and osteocalcin levels (to establish baseline values); selective blood samples for exploratory analysis; blood safety tests (hematology, serum chemistry) and urine pregnancy test for WOCBP; concomitant medication and AE monitoring; urinalysis.
[0280] Maborixaphor administration begins on D1 and is administered daily for 6 months. The dose of maborixaphor for adults is 400 mg QD. For adolescents weighing >50 kg (12 to <18 years), the dose of maborixaphor is 400 mg QD. For adolescents weighing ≤50 kg, 200 mg QD of maborixaphor is administered. Dose reduction is permitted only for tolerability or safety reasons and only with the written approval of the medical monitor and the sponsor.
[0281] Treatment evaluation includes the following:: Infection assessment throughout the treatment period (Note: Infection assessment must be performed before all other procedures); PRO, ClinRO, and Bone Pain and G-CSF Burden Questionnaires for M1, M3, and M6 (Note: PRO, ClinRO, and Bone Pain and G-CSF Burden Questionnaires must be performed after the infection assessment and before other scheduled assessments); Symptomatic physical examination for D1, M1, M3, and M6; body weight at time point 0 for D1, M1, M2, M3, M4, M5, and M6; vital signs (HR, BP, and temperature) for D1, M1, M2, M3, M4, M5, and M6; ECG at time point 0 and 2 hours (± 15 minutes) after administration for D1, M1, and M6 (Note: If performed on the same day, the ECG must be performed before blood collection); consider G-CSF dose adjustment for M2, M3, M4, M5, and M6; Blood collection and PK sampling to monitor ALC, AMC, ANC, and WBC levels are performed at the following time points in D1, M1, M3, and M6: 0 (before administration and up to 15 minutes prior), 60 minutes (± 5 minutes) after administration, and 2, 3, 4, 6, and 8 hours (± 15 minutes each) (Note: To avoid diurnal variation, the 8-hour blood sample collection must be performed at the same time point(s) as the previous visit); peak and trough PK sampling and ALC, AMC, ANC, and WBC sampling are performed in M2, M4, and M5 (Note: Trough is defined as before administration (Time Point 0), and peak is defined as 2 to 4 hours after administration); phenotypic analysis / gene expression profiling evaluated by EpiID or qPCR at Time Point 0 (before administration) and 4 and 8 hours after administration (± 15 minutes each) in D1, M1, and M6; Selective blood samples for exploratory analysis at M1, M3, and M6; G-CSF, cytokine, and osteocalcin levels at D1, M1, M6, and the 30D visit after EOT; ophthalmic examination at M6 (all study participants).The M6 EOT ophthalmic examination period is extended until the end of the safety follow-up visit period; endocrine evaluation of the HPG axis in a fasting state for testicular safety testing in M6 (male participants) (Note: Male participants (12 to ≤ 50 years of age) are recommended to fast for 12 hours prior to hormone testing); blood safety tests (hematology, serum chemistry) and urine pregnancy test for WOCBP (Note: If an infection occurs during the study, the participant may receive any Standard of Care (SOC) including antibiotics and / or procedures (i.e., abscess drainage); verification of Maborixaphor compliance; concomitant medication and AE monitoring at every visit; urinalysis at every visit.
[0282] The safety of participants is monitored throughout the study. The investigator may perform additional blood draws to monitor participant safety. All participants are scheduled for an EOT follow-up visit 30 days (± 14 days) after the EOT.
[0283] Post-treatment evaluation includes the following: : Infection assessment; (Note: Infection assessment must be performed prior to all other procedures); administration of PRO, ClinRO, and bone pain and G-CSF burden questionnaires (Note: PRO, ClinRO, and the questionnaires administered must be performed after infection assessment and before other scheduled assessments); symptomatic physical examination; weight; vital signs (HR, BP, and temperature); ECG at time points 0 and 2 hours (± 15 min); one-time ALC / AMC / ANC / WBC blood draw (optional); G-CSF, cytokine, and osteocalcin levels at the D1, M1, M6, and 30D visits after EOT; blood safety tests (hematology, serum chemistry, and serology) and urine pregnancy test for WOCBP (Note: If an infection occurs during the study, the participant may receive any standard of care (SOC), including antibiotics and / or procedures (i.e., abscess drainage); concomitant medications and AE monitoring; urinalysis.
[0284] Unscheduled visits in Part 1 or Part 2 may be made for any medically justifiable reason. These visits may be made in person or by telephone. If conducted remotely, any clinically necessary laboratory tests shall be performed using a local laboratory and entered as unscheduled test results (identified as infection-related). These tests may include, at the investigator's discretion, complete blood counts (including but not limited to ANC), cultures, C-reactive protein, imaging studies, and any other relevant assessments.
[0285] Requests for home visits are reviewed and approved on a case-by-case basis. Home visits are an applicable option for all study visits, including screening and baselines. Every effort is made to conduct home visits to the same standards as in-person visits. If random assessments are not collected during a home visit, this is documented as a protocol deviation, and the investigator or designated person is followed up by phone or at the next scheduled visit to confirm that the missed assessment did not affect participant safety.
[0286] Enroll a total of up to approximately 50 participants. Of the 50 enrolled participants: plan to enroll no more than approximately 40 participants diagnosed with CIN; plan to enroll no more than approximately 3 participants diagnosed with cyclic neutropenia; and plan to enroll no more than approximately 7 participants diagnosed with congenital neutropenia. Make every effort to enroll at least 20 participants who are not receiving G-CSF treatment across all disease state subtypes.
[0287] [Table 2]
[0288] Maboric Sapor's potential at risk Korea Monitoring and management procedure
[0289]
[0290]
[0291] Participant Inclusion Criteria : All participants (Part 1 and Part 2) must meet the following: sign the ICF and have the willingness and ability to comply with the protocol; be ≥ 12 years of age at the time of signing the ICF; weigh ≥ 15 kg; and if sexually active, agree to use highly effective contraception; participants may be eligible for the study regardless of whether they are receiving G-CSF treatment (Note: Participants receiving G-CSF treatment must maintain a stable dose for ≥ 14 days prior to the baseline visit); (Note: Participants receiving G-CSF treatment have no lower ANC limit at the screening visit, but ANC must not be ≥ 10,000 cells / μL); (Note: Participants not receiving G-CSF treatment must have discontinued G-CSF for ≥ 14 days prior to the baseline visit and ANC ≤ 1,000 cells / μL at the screening visit Must be L); Must have been diagnosed with chronic neutropenia not attributable to medication, active or recent (≤ 3 months) infection, or malignant causes at least 6 months prior to the screening visit (Note: Participants with Schwakmann-Diamond syndrome, Cohen syndrome, and WHIM syndrome are eligible. Other types of chronic neutropenic disorders may also be enrolled after discussion and approval with the sponsor and study medicine monitor); Participants with congenital neutropenia must have genetic test results prior to study enrollment, unless they declined genetic testing; Part 2: Participants enrolled in the study prior to the implementation of Protocol Version 8.0 must have completed Part 1 and demonstrated a positive response to treatment (i.e., a twofold increase in baseline ANC or reaching ANC ≥ 1,500 cells / μL after D1 administration); Part 2: The participant has a history of symptomatic chronic neutropenia identified by the investigator.
[0292] Participants with any of the following are excluded from the study: known systemic hypersensitivity to Maborixafor active ingredient or its inactive component; being pregnant, breastfeeding, or planning to become pregnant within the next 8 months; a known history of serological positivity for HIV or viral load, or a known history of acquired immune deficiency syndrome; known active SARS-CoV-2 virus (COVID-19) infection or a positive test result according to locally recognized clinical and government guidelines regarding the infectious period (Note: Participants with prior COVID-19 exposure are permitted to enroll if their test result is negative and they comply with local guidelines); (At the screening visit, having laboratory test results meeting one or more of the following criteria: positive for hepatitis C virus (HCV) antibodies confirmed by HCV-ribonucleic acid polymerase chain reaction reflex test; positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Note: If a participant is HBsAg negative but HBcAb positive, the participant is considered eligible if the antibody reflex test for HBsAg is positive.)); (At the screening visit, having laboratory test results meeting ≥ 1 of the following criteria: hemoglobin < 9.0 g / dL; platelets < 30,000 / μL; estimated glomerular filtration rate (eGFR) ≤ 60 mL / min / 1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; serum aspartate transaminase > 2.5 times the upper limit of normal (ULN); serum alanine transaminase > 2.5 times the ULN; total bilirubin > 1.5 times the ULN.5 times (excluding cases due to Gilbert's syndrome, in which case total bilirubin ≥ 3.0 times ULN and direct bilirubin > 1.5 times ULN)); (received any of the following treatments within 14 days prior to D1: systemic glucocorticoids (> 5 mg prednisone equivalent per day); drugs prohibited due to potential CYP2D6 interactions); presence of an infection requiring systemic antibiotics within 4 weeks prior to the baseline visit; Having a medical or personal condition that could potentially jeopardize the participant's safety, hinder the successful completion of the clinical study, or, in the opinion of the investigator or sponsor, interfere with the purpose of the study (e.g., poorly controlled chronic conditions such as hypertension, diabetes, coronary disease, congestive heart failure, asthma, chronic obstructive pulmonary disease, and cardiac arrhythmia); having undergone major surgery within 4 weeks prior to the baseline visit; being unable to take Maborixafor capsules; having a history of active malignancy or solid, metastatic, or hematological malignancy within 5 years prior to study enrollment (exception: appropriately treated basal cell carcinoma in situ of the skin); being diagnosed with or suspected of having congenital long QT syndrome.A history of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or torsades de pointes); if there is a history of arrhythmia, discuss with the sponsor's medical monitor prior to participant enrollment in the study; corrected QT interval prolongation (> 450 ms) calculated using the Fridericia (QTcF) formula on the screening visit ECG.
[0293] For the safety of the participants and to facilitate the evaluation of both safety and therapeutic efficacy, participants in this study are asked to agree to the following restrictions during the study: not to start new prescription medications unless prescribed or approved by the investigator or necessary in an emergency; not to take any over-the-counter medications unless directed or approved by the investigator; and not to consume grapefruit, grapefruit juice, or products containing Seville oranges, which are variable inhibitors of CYP3A4 and are prohibited. Seville oranges (or bigarades) are particularly tart oranges commonly used to make marmalade. During this study, participants must not consume or use marmalade, oil, powder, or preserved foods containing oranges or orange flavor, and must consume only fresh oranges that participants know are not Seville oranges; (Fasting: Each participant receives either Mavorixafor or a placebo in the morning. Participants are instructed to refrain from all food and beverages (except water) overnight (≥ 10 hours) and to fast for 30 minutes after administration; the study treatment (Mavorixafor or placebo capsule) must be swallowed whole and must not be chewed or crushed. Male participants (12 to ≤ 50 years of age) are recommended to fast for 12 hours prior to baseline (before administration) and hormone tests performed at M6 (Note: Participants experiencing significant difficulties due to schedule requirements and dietary restrictions should consult with a medical monitor to develop the most effective regimen possible)).
[0294] Prophylactic medications, treatments, and procedures for female and male participants of childbearing age WOCBP is defined as any female participant who has had her first menstruation, is not postmenopausal, or has not undergone documented hysterectomy, bilateral salpingoligomy, or bilateral oophorectomy.
[0295] Postmenopausal status is defined as the absence of menstruation for at least 12 months without an alternative medical cause. High FSH levels in the postmenopausal range can be used to confirm postmenopausal status in women who are not using hormonal contraception or hormone replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient, and the participant must use a highly effective method of contraception.
[0296] All sexually active women, regardless of fertility, must use highly effective contraception from screening, throughout study participation, and for at least 4 weeks after the last administration of maborixafor. Acceptable methods include: systemic hormonal contraceptives used in combination with additional barrier methods (e.g., male condoms); combined (containing estrogen and progesterone) hormonal contraceptives associated with ovulation suppression (oral, vaginal, or transdermal); progesterone-only hormonal contraceptives associated with ovulation suppression (oral, injectable, or implantable); intrauterine devices; intrauterine hormone-releasing systems; bilateral tubal occlusion; a partner who has undergone a vasectomy and has received a medical evaluation of the success of the procedure (if such partner is the only sexual partner); sexual abstinence (refraining from sexual intercourse with the opposite sex during the entire risk period associated with the study treatment). The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the participant's preferred usual lifestyle; and double-barrier contraceptive methods, such as condoms with spermicide, are acceptable.
[0297] All WOCBPs undergo a serum pregnancy test at screening and a urine pregnancy test at every subsequent visit; a negative result is required to dispense Maborixafor. WOCBPs must notify the institution if they have missed their period. Pregnant participants must discontinue participation in the study.
[0298] All female participants who were not yet of childbearing age at the time of study enrollment must report the date of their first menstruation to the investigator or designated person, and at each visit, the investigator or designated person asks all female participants enrolled in the study who had not had their first menstruation at the time of screening whether or not their first menstruation has occurred.
[0299] Men of childbearing age must use male condoms (including spermicides) with a sexual partner who is a WOCBP from screening through study participation and up to 4 weeks after the last administration of maborixapor.
[0300] Reason for withdrawal or termination Part 1 study completion is defined as the completion of the 1-day administration of Maborixafor and an additional 7 (+ 2) safety follow-up period following administration. Part 2 study completion is defined as the completion of the 6-month QD administration of Maborixafor and the 30-day safety follow-up visit following the EOT. To consistently aggregate participant status, the investigator or designated person shall complete the appropriate electronic case report form (eCRF) and select the primary reason for withdrawal from the following standard categories: Any AE indicating the reason for discontinuing Maborixafor (clinical or laboratory, significant or non-significant, regardless of relevance to Maborixafor), including the investigator's medical judgment based on the participant's best interests; withdrawal of consent by the participant; loss of follow-up—the participant discontinued visits; the sponsor terminated the study for any reason; or other reasons where the investigator determined it was necessary to discontinue the participant's participation in the study (e.g., low adherence, chemotherapy, etc.).
[0301] Capacity adjustment: If a participant receiving study treatment experiences an AE suspected to be associated with maborixafor with a Common Terminology Criteria for Adverse Events (CTCAE) grade ≥2, the study drug may be managed as follows: maborixafor may be withheld (discontinued) until the AE improves to grade ≤ 1; in case of safety concerns, the investigator or the designated person is permitted to discontinue maborixafor and notify the medical monitor. As necessary regarding the AE and changes in treatment, measures required for study treatment may be determined in consultation with the Data Monitoring Committee (DMC).
[0302] Certain agents that are substrates of CYP2D6 are prohibited. If a potent CYP3A4 inhibitor is required, the investigator should contact the medical monitor. If the investigator and the medical monitor conclude that one of these drugs should be used, the 400 mg QD dose of maborixafor is reduced. If the potent inhibitor is discontinued, the participant returns to the 400 mg QD dose. For adolescent participants aged 12 to < 18 years at screening and weighing ≤ 50 kg, if concomitant administration with a potent CYP3A4 inhibitor is required, the dose of maborixafor may be reduced from 200 mg to 100 mg, but may be maintained at 200 mg QD under appropriate medical monitoring. In other situations where dose reduction may be considered appropriate, the investigator consults with the medical monitor. In emergency situations where the prohibited agent cannot be avoided after the first dose of study treatment; the investigator may prescribe the prohibited agent and suspend study treatment. The investigator reports the emergency use of the prohibited agent to the medical monitor within 24 hours. Finally, in the case of documented safety concerns, the investigator is permitted to reduce the dose of maborixafor and notify the medical monitor.
[0303] Efficacy evaluationMeasure ALC, AMC, ANC, and WBC to calculate AUC.
[0304] In Part 1, intensive ALC, AMC, ANC, and WBC sampling are performed at the following time points: on D-1 (baseline) at time points 0, 60 min (± 5 min), and 2, 3, 4, 6, and 8 hours (± 15 min each); on D-1 at time point 0 (before administration and up to 15 minutes prior), 60 min (± 5 min) after administration, and 2, 3, 4, 6, and 8 hours (± 15 min each). Absolute lymphocyte counts, AMC, ANC, and WBC are determined by standard methods. Whole blood samples are sent to the central laboratory selected by the client (Note: If central laboratory analysis is not available, whole blood samples may be analyzed at a local laboratory).
[0305] Blood samples are taken at baseline (D-1) at time point 0 (before administration) and at 4 and 8 hours after administration (± 15 minutes, respectively) to monitor the immunophenotype profile of lymphocyte subpopulations evaluated by FACS. FACS analysis consists of the following marker panels: CD3 / CD4 (T helper cells), CD3 / CD8 (cytotoxic T cells), CD4 / CD8 ratio, CD19 (B cells), and CD16 / CD56 (NK cells). Other markers may be measured.
[0306] In Part 2, intensive ALC, AMC, ANC, and WBC sampling are performed at the following time points: at time points 0, 60 minutes (± 5 minutes) and 2, 3, 4, 6, and 8 hours (± 15 minutes each) on D-3 to D-1 (baseline); at time points 0 (before administration and up to 15 minutes prior), 60 minutes (± 5 minutes) after administration and 2, 3, 4, 6, and 8 hours (± 15 minutes each) on D1, M1, M3, and M6.
[0307] Blood samples are evaluated by EpiID / qPCR to monitor the phenotype analysis / gene expression profile of lymphocyte subpopulations. Measurements are taken at time points 0, 4 hours (± 15 min), and 8 hours (± 15 min) at baseline (D-3 to D-1), and at time points 0 (before administration and up to 15 minutes prior) and 4 hours and 8 hours after administration (± 15 min, respectively) at D1, M1, and M6.
[0308] In Part 2, peak and trough ALC, AMC, ANC, and WBC sampling are performed on M2, M4, and M5 (Note: Trough is defined as before administration (time 0) and peak is defined as 2 to 4 hours after administration).
[0309] Selective blood samples for exploratory analysis, including but not limited to whole blood and bone-specific alkaline phosphatase isoenzymes for immunophenotype analysis of PBMC, CD34+ cells, and neutrophils, and whole blood and bone-specific alkaline phosphatase isoenzymes for phagocytosis assay, are evaluated at time points 0, 4 hours (± 15 min), and 8 hours (± 15 min) of baseline (D-3 to D-1), and at time points 0 (before administration and up to 15 minutes prior) and 4 hours and 8 hours (± 15 min) after administration (each) of D1, M1, M3, and M6.
[0310] Examples 2: Recurrent and / or serious infection experiencing congenital and Acquired primary autoimmune and idiopathic chronic Neutropenia obstacle From the participants Maboric Sapor's Phase 3 Random, Double-blind, Penalty contrast, Multi-agency research
[0311] A two-part open-label, multicenter study of maborixapor (X4P-001) will be conducted on participants diagnosed with chronic neutropenia.
[0312] [Table 3]
[0313] research purpose and Evaluation variables
[0314]
[0315]
[0316] Overall Design Summary To be eligible for the study, participants must be diagnosed with congenital or acquired primary autoimmune and idiopathic CN disorders. Participants must be ≥ 12 years of age, have an ANC < 1000 cells / μL at screening (a single ANC value in hematology), be confirmed to have a mean ANC < 1000 cells / μL at baseline, and meet all eligibility criteria. Participants are included in the study regardless of their current background therapy (where background therapy is defined as the participant's current treatment regimen, options including but not limited to G-CSF, immunoglobulin replacement therapy, prophylactic antibiotics, or "waiting for observation"). All participants must have experienced sequelae of CN, specifically at least two recurrent and / or serious infections requiring antibiotic use (intravenous / oral) and / or visits to a medical facility (including but not limited to emergency room visits, urgent care facilities, primary care physician offices, or inpatient treatment) within the past 12 months; Therefore, patients receiving background therapy are experiencing recurrent and / or serious infections that are not adequately controlled despite the use of current treatment regimens.
[0317] Participants are stratified according to the type of CN (innate or acquired primary autoimmune and idiopathic) and baseline G-CSF use, and randomized into the following two groups in a 1:1 ratio: Group 1 includes participants receiving maborixafor + background therapy. Group 2 includes participants receiving placebo + background therapy.
[0318] G-CSF administration (dosage and schedule) is maintained throughout the study, except for dosage changes permitted for safety reasons. After signing the Informed Consent Form (ICF) / Consent, participants provide a buccal sample to complete genetic screening for genetic variations in genes included in the Comprehensive Immunity and Cytopenia Panel to characterize the participant's CN type. Those with confirmed previous genetic test results indicating the presence of known pathogenic variants associated with CN confirming classification as congenital are not required to provide this sample. Bone marrow aspirates or biopsies are collected during the screening visit from all participants who lack documentation regarding a bone marrow aspirate or biopsy within the past nine months. Samples stored within the past nine months may be tested locally for eligibility review. Participant eligibility is assessed during the screening visit.
[0319] Maborixafor or placebo is administered to the participants. Adults (≥ 18 years) are administered 400 mg of maborixafor or placebo once daily (QD). Adolescents (≥ 12 to < 18 years) weighing > 50 kg are administered 400 mg of maborixafor or placebo QD. Adolescents (≥ 12 to < 18 years) weighing ≤ 50 kg are administered 200 mg of maborixafor or placebo QD.
[0320] Administer the first dose of the study treatment on day 1. Perform an electrocardiogram (ECG) before administering the study drug, and then collect blood at t = 0. After the ECG and blood collection, administer the dose of the study drug (within 15 minutes). After administration, perform an ECG 2 hours (± 30 minutes), and then collect blood at t = 2 hours (± 15 minutes).
[0321] Approximately 24 to 72 hours prior to each scheduled study visit, the participant is called to confirm if they feel they may have an ongoing infection, and the participant is reminded not to take the study treatment at home, as it will be administered during the visit on the day of the visit. If symptoms consistent with an infection are present, every effort is made to proceed with the scheduled visit to collect safety information and manage / dispense the study treatment. Once the infection has resolved, an additional non-scheduled visit is conducted to collect efficacy data.
[0322] Treatment Period: Participants receive daily blinded study treatment from Day 1 until the 52-week / 365-day visit. Participants who complete the 52-week / 365-day visit are offered the option to participate in a separate long-term extension study. Participants who choose to participate in the long-term follow-up study will be provided with open-label Maborixafor until Maborixafor becomes commercially available or the sponsor terminates the study.
[0323] If a participant discontinues the study early for any reason other than withdrawal of consent, an early termination (ET) follow-up is completed. If the investigator deems it necessary, an end-of-study (EOS) / safety follow-up visit is conducted after an in-person ET visit. The EOS visit is conducted at the Week 52 / Day 365 visit or 30 days (± 14 days) after the ET visit.
[0324] Objectives and Evaluation Variables The purpose and evaluation variables of this study are summarized in Table 4.
[0325] [Table 4]
[0326] purpose and Evaluation variables
[0327]
[0328]
[0329] eligibility : To be eligible for a Phase 3 randomized, double-blind, placebo-controlled study, participants must be diagnosed with congenital or acquired primary autoimmune and idiopathic CN disorders. Participants must be ≥ 12 years of age, have an ANC < 1000 cells / μL (single ANC value in hematology) during screening, be confirmed to have a mean ANC < 1000 cells / μL at baseline, and meet all eligibility criteria.
[0330] All participants must have experienced sequelae of CN, specifically at least two recurrent and / or serious infections requiring antibiotic use and / or visits to a medical facility in the past 12 months (see Section 5.1); thus, patients receiving background therapy are experiencing recurrent and / or serious infections that are not adequately controlled despite the use of current therapy regimens.
[0331] Treatment group Participants are stratified according to the type of CN (congenital or acquired primary autoimmune and idiopathic) and whether G-CSF was used in screening, and are randomized into the following two groups in a 1:1 ratio: Group 1 includes participants receiving maborixafor + background therapy. Group 2 includes participants receiving placebo + background therapy. (Note: Background therapy is defined as the participant's current treatment regimen. Options include, but are not limited to, G-CSF, immunoglobulin replacement therapy, prophylactic antibiotics, or "wait and see." Up to 40% of enrolled participants receive chronic G-CSF background therapy.) Enrollment of participants with congenital neutropenic disorders associated with bone marrow failure may be limited to approximately 15. If genetic testing does not reveal the presence of known pathogenic variants associated with CN confirming a congenital classification, the type of CN is determined at the investigator's clinical judgment.
[0332] G-CSF administration (dosage and schedule) is maintained throughout the study, except for dosage changes permitted for safety reasons. Participants are informed of the value of genetic screening during discussions regarding study design and objectives. After signing the Informed Consent Form (ICF) / Consent, participants provide a buccal sample to complete genetic screening for genetic variations in genes included in the Comprehensive Immunology and Cytopenia Panel to characterize the participant's CN type. Individuals with confirmed previous genetic test results indicating the presence of known pathogenic variants associated with CN confirming a classification as congenital are not required to provide this sample. Bone marrow aspirates or biopsies are collected as part of the screening visit for patients without documented records of a bone marrow aspirate or biopsy within the past nine months. Samples stored within the past nine months may be tested locally for eligibility review.
[0333] If, in the investigator's opinion, a systemic infection that may affect ANC is present between the screening visit and the baseline visit, the baseline visit is postponed or repeated as deemed appropriate by the investigator to confirm a trough ANC < 1000 cells / μL. The screening and baseline visit procedures may be repeated locally (screening visit only) or centrally (screening or baseline visit) as deemed appropriate by the investigator due to the influence of infection, G-CSF dose timing, circadian rhythm, or other concomitant medications. Repeated measurements must be based on grounds that the measurement will change and should be limited to three times for any single type of event. If the infection persists longer than the screening period (70 days), the participant must reconfirm eligibility criteria (including laboratory tests). The systemic infection must be resolved prior to the first administration of the study treatment. If an infection occurs at any time between screening and the administration of the first dose of the study drug, this event is recorded as an unrelated AE.
[0334] Administer Maborixafor or a placebo to the participants. Administer 400 mg of Maborixafor or a placebo QD to participants whose body weight > 50 kg. Administer 300 mg of Maborixafor or a placebo QD to participants whose body weight ≤ 50 kg.
[0335] Instruct the participant to fast from all food and beverages (except water) overnight and to fast for 30 minutes after administration.
[0336] The first dose of the study treatment is administered on the morning of the first day, followed by an ECG 2 hours (± 30 minutes) after administration and blood collection between 2 and 4 hours (± 30 minutes) after administration.
[0337] To avoid repeated punctures, indwelling catheters may be used for blood sampling for PK, ALC, absolute monocyte count (AMC), ANC, and WBC. During the study, information regarding potential infection is collected through multiple sources, including patient-reported outcomes (PRO) questionnaires and information collected by the investigator and the study team. Potential infection events are evaluated by a blind, independent Adjudication Committee (AC) as set forth in the AC Charter. The AC evaluates all potential infection data and determines whether the event corresponds to an infection, the characteristics of the infection, the severity of the infection, and whether the participant can continue participating in the study. For the purposes of efficacy analysis, the AC makes the final determination regarding infection events.
[0338] Call the participant approximately 24 to 72 hours prior to each scheduled study visit to confirm if they perceive an ongoing infection; remind the participant not to take the study treatment at home, as it will be administered during the visit; and confirm with the participant that G-CSF administration is being appropriately withheld prior to the visit. If symptoms consistent with an infection are present, make every effort to proceed with the scheduled visit to collect safety information and manage / dispense the study treatment. Once the infection has resolved, an additional non-scheduled visit must be conducted to collect efficacy data.
[0339] Participants receive daily blinded study treatment from Day 1 until the Week 52 / Day 365 visit. Participants who complete the Week 52 / Day 365 visit are given the option to participate in a separate long-term extension study. Participants who choose to participate in the long-term extension study are provided with open-label Maborixafor until Maborixafor becomes commercially available or the sponsor terminates the study. For participants who discontinue the study early, an Early Termination (ET) visit is conducted (except where the participant withdraws consent), followed by an End of Study (EOS) / Safety Follow-up visit.
[0340] Inclusion criteria Participants may be included in the study only if all of the following criteria apply: Participants must be at least 12 years of age at the time of signing informed consent / approval in accordance with local regulations and guidelines.
[0341] Patient type: Diagnosed with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorder not attributable to drugs, active or recent infection, or malignancy at least 6 months prior to the screening visit; congenital neutropenia including, but not limited to, the following classifications: solitary with a permanent (non-cyclic) pattern, e.g., ELANE, CSF3R, CXCR2, WAS; associated with extrahematological symptoms, e.g., Barth syndrome, Cohen syndrome, G6PC3, Kostmann disease; associated with metabolic disorders, e.g., glycogen storage disease 1b (GSD1b); Schwakmann-Diamond syndrome; acquired primary neutropenia: chronic idiopathic neutropenia, primary autoimmune neutropenia.
[0342] Other CN disorders that may be eligible for enrollment can be clarified and approved after discussion with the research medicine monitor and the sponsor:
[0343] During screening, have an ANC < 1000 cells / μL (a single ANC value in hematology) and, in the absence of clinical evidence of infection, have the lowest mean ANC confirmed at the baseline visit (average of multiple ANC measurements over 6 hours). (Note: If, in the investigator's opinion, there is a systemic infection that may affect ANC between the screening visit and the baseline visit, the baseline visit may be postponed or repeated as deemed appropriate by the investigator to confirm the lowest ANC < 1000 cells / μL. Repeat measurements must be based on grounds that the measurement may have changed and must be limited to three for any single type of event;
[0344] A history of recurrent and / or serious infection (i.e., sequelae of CN) within the 12 months prior to the screening visit is defined as having at least two infections within the past 12 months that meet the following criteria: an infection requiring the use of antibiotics (intravenous [IV] / oral), or an infection requiring a visit to a medical facility (including, but not limited to, emergency room visits, urgent care facilities, primary care physician offices, or inpatient treatment); and for all potential participants: an infection that the investigator determines is likely to be associated with the potential participant's CN impairment.
[0345] Note: Oral ulcers (i.e., oral ulcers, aphthous ulcers) are sequelae of CN but are not considered new infections for eligibility purposes. If findings of oral ulcer(s) and / or oral mucositis are judged to be exacerbated by or resulting from an infection, e.g., a fungal etiology, they may be considered an infection. Recurrent herpes simplex virus (HSV) or human papillomavirus (HPV) oral or genital lesions are not classified as infections for the purposes of this study. If these lesions show signs of a secondary bacterial or fungal infection, they may be considered an infection. Gingivitis is not considered an infection. Periodontitis may be considered an infection.
[0346] Participants using G-CSF or other active background therapy must have received these therapies for ≥ 12 months, maintained a stable dose and administration schedule for ≥ 4 weeks prior to the screening visit, and maintained this dose and administration schedule throughout the study (Note: For patients receiving chronic G-CSF treatment, a change in administration may be considered for safety reasons [e.g., when ANC > 10,000 cells / μL is ≥ 4 weeks]).
[0347] Participants must be willing to maintain a stable dose / therapy of G-CSF or other background therapy during the study period (except for safety reasons). The following drugs are prohibited: (a) drugs that are primarily metabolized by CYP2D6 or are sensitive substrates of CYP2D6 are prohibited during the study, starting from the longer of 14 days or 5 half-lives prior to administration of the study drug; and (b) drugs that are potent CYP3A4 inducers are prohibited during the study, starting from the longer of 7 days or 5 half-lives prior to administration of the study drug. If the investigator and medical monitor conclude that a potent inhibitor of CYP3A4 should be used, the dose of Maborixafor should be changed. Products containing grapefruit and Seville orange, which are variable inhibitors of CYP3A4, are prohibited during the study starting from the day the first dose of the study drug is administered. Bone marrow biopsies or aspirates taken during screening (or previously documented data regarding bone marrow biopsies or aspirates within the last 9 months) must not show evidence of hematological malignancy. The use of contraception by men and women must be consistent with local regulations regarding contraceptive methods for clinical study participants.
[0348] Exclusion criteria : Participants are excluded from the study if any of the following apply (1-21):
[0349] 1. Diagnosis of secondary neutropenia including that caused by: hypersplenomegaly; infection; malignancy; autoimmune diseases, e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, graft-versus-host disease, thyroid disease; nutritional deficiencies, e.g., vitamin B12, folic acid, copper, caloric malnutrition; drug-induced causes, e.g., chemotherapy, clozapine, antiretroviral agents, antibiotics, monoclonal antibodies.
[0350] 2. Diagnosis of any of the following: aplastic anemia; WHIM syndrome; certain congenital neutropenia, including but not limited to the following classifications, are excluded: (isolated form with a cyclic pattern, e.g., ELANE; those associated with immunomodulatory disorders, e.g., autoimmune lymphoproliferative syndrome, familial hemophagocytic lymphohistiocytosis, Chediac-Higashi syndrome (Ch diak-Higashi syndrome); those associated with bone marrow failure, e.g., Fanconi anemia, Diamond-Blackfan anemia, telomere biology disorders; neutropenia associated with the Duffy-null phenotype (formerly known as benign ethnic neutropenia).
[0351] 3. A known history of serological positivity for HIV or viral load, or a known history of acquired immunodeficiency syndrome.
[0352] 4. A positive test for known active COVID-19 infection or transmissible period in accordance with locally recognized clinical and government guidelines. (Note: Participants with prior COVID-19 exposure are permitted to enroll if they test negative and comply with local guidelines.)
[0353] 5. Major surgery requiring general anesthesia within 6 weeks prior to the baseline visit or which, in the investigator's opinion, may compromise the participant's safety.
[0354] 6. A medical or personal condition that could potentially impair the safety of the participant, hinder the successful completion of the clinical study by the participant, or, in the opinion of the investigator or sponsor, interfere with the purpose of the study.
[0355] 7. History of active malignancy or solid or hematological malignancy within 5 years prior to study enrollment. Exception: Adequately treated basal cell carcinoma in situ of the skin.
[0356] 8. Patients awaiting HSCT due to somatic mutations in genes associated with a high risk of clonal proliferation.
[0357] 9. History of diagnosed or suspected congenital long QT syndrome or clinically significant (CS) ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, or Torsade de Pointe). If there is a history of arrhythmia, discuss it with the sponsor's medical monitor before the participant enrolls in the study.
[0358] 10. Taking or requiring any prohibited drug / therapy
[0359] 11. Received more than one dose of Maborixafor in the past.
[0360] 12. Received CXCR4 antagonists (excluding mavorixafor) during the past 6 months.
[0361] 13. Patients receiving pegylated G-CSF, except those diagnosed with congenital neutropenia confirmed by screening.
[0362] 14. Positive for Hepatitis C virus (HCV) antibodies confirmed by HCV ribonucleic acid polymerase chain reaction reflex test.
[0363] 15. Positive for hepatitis B surface antigen (HbsAg) or hepatitis B core antibody (HbcAb). If a participant is negative for HbsAg, positive for HbcAb, and positive for hepatitis B surface antibody on a reflex test, the participant is considered eligible.
[0364] 16. Laboratory test results meeting ≥ 1 of the following criteria at the screening visit: Hemoglobin < 9.0 g / dL; Platelets < 30,000 / μL; Glomerular filtration rate estimated by the Synergistic Equation for Chronic Kidney Disease (age ≥ 18 years) or the Schwartz Equation (age 12–17 years) ≤ 60 mL / min / 1.73 m2; Serum aspartate transaminase > 2.5 times the Upper Limit of Normal (ULN); Serum alanine transaminase > 2.5 times the ULN; Total bilirubin > 1.5 times the ULN (excluding cases due to Gilbert's syndrome, in which case Total bilirubin ≥ 3.0 times the ULN and Direct bilirubin > 1.5 times the ULN)
[0365] 17. Extended corrected QT interval > 450ms using the Fridericia formula at the screening visit.
[0366] 18. The participant is currently receiving the investigational drug or received it within the longer of < 30 days or 5 half-lives prior to the screening visit.
[0367] 19. The participant is pregnant or breastfeeding.
[0368] 20. Unable to swallow the capsule and / or unwilling to swallow it.
[0369] 21. Known systemic hypersensitivity to Maborixaphor active ingredient, its inactive component, or placebo.
[0370] Analysis of primary evaluation variables : Determine the following primary efficacy endpoints in the ITT subgroup and ITT group of participants not receiving G-CSF treatment:
[0371] 1. Infection rate based on infection assessed by a blinded, independent AC during a 12-month treatment period
[0372] 2. The proportion of participants who meet the definition of a positive ANC response in at least two of the three visits (weeks 4, 8, and 13) during the first three months, defined as follows: ANC ≥ 1500 cells / μL, excluding participants with a baseline ANC < 500 cells / μL; and for participants with a baseline ANC < 500 cells / μL, an increase of at least twofold from the baseline ANC.
[0373] Supportive evaluation variables :
[0374] For ANC responders only, the duration of a positive ANC response is defined as the time from the first positive ANC response until the disappearance of the positive ANC response without subsequent resumption of response, wherein the disappearance of the ANC response is defined as an event satisfying one of the following criteria on at least two consecutive visits: a decrease in the ANC level of a participant with a baseline ANC ≥ 500 cells / μL to <1,500 cells / μL; a decrease in the ANC level of a participant with a baseline ANC <500 cells / μL to <500 cells / μL.
[0375] In participants not receiving chronic G-CSF, the duration of a positive ANC response only for ANC responders.
[0376] Proportion of participants with an overall positive ANC response during the 12-month treatment period.
[0377] Absolute and fold changes from baseline of total ALC, absolute monocyte count, ANC, and leukocyte count at each visit during the 12-month treatment period.
[0378] Examples 3: Healthy From the applicant Maboric Sapor's Diet effect
[0379] The pharmacokinetics, safety, and tolerability of maborixafor were evaluated in healthy participants in fasting and feeding states in a randomized, Phase I, open-label, single-center, single-dose, 6-period, 6-order crossover study.
[0380] Maborixafor was administered in a random order under six different conditions: Condition A: MAV dose after at least 10 hours of nighttime fasting; Condition B: at least 10 hours of nighttime fasting, high-fat meal (ingested within 30 minutes) + MAV immediately after the meal; Condition C: at least 10 hours of nighttime fasting, low-fat meal (ingested within 30 minutes) + MAV immediately after the meal; Condition D: at least 10 hours of nighttime fasting, MAV administration + low-fat meal 30 minutes after MAV (ingested within 30 minutes); Condition E: at least 4 hours of afternoon fasting, high-fat meal (ingested within 30 minutes) + MAV in the evening (2 hours after the meal was completed); Condition F: at least 4 hours of afternoon fasting, MAV administration. Except for Condition D, no food or drink was permitted after MAV administration.
[0381] Fig. 1 Silver Maboric Sapor C max It shows the effects of feeding and fasting status on C. Compared to the fasting state (10 hours), subjects in the feeding (high-fat) and feeding (low-fat) groups max ... decreased by -66% and -55%, respectively. Similarly, compared to fasting subjects (low-fat after administration), subjects who underwent afternoon fasting (4 hours) or afternoon fasting (4 hours) administered 2 hours after high-fat food intake C max decreased by -59% and -43%, respectively. AUC was also measured under the same conditions ( Fig. 2 The feeding (high-fat) and feeding (low-fat) groups showed a decrease in AUC of -55% and -51%, respectively, compared to the fasting group (10 hours). The fasting group accompanied by low-fat (30 minutes after administration) showed a relative decrease in AUC of -18%, whereas the afternoon fasting (4 hours) and afternoon fasting (4 hours) groups administered 2 hours after high-fat food intake showed a decrease in AUC of -37% and -24%, respectively.
[0382] These observations can be explained as follows: Maborixaphor is readily soluble in the pH range of 1.0 to 5.5 (> 70 mg / mL), slightly soluble at pH 6.8 (22 mg / mL), and slightly soluble at pH 7.5 (3.3 mg / mL). The elevated pH after food intake may have reduced the solubility of Maborixaphor, thereby reducing absorption and exposure. Therefore, Maborixaphor is soluble at all pH values between 1.0 and 5.5 tested, which includes the gastric pH range expected to be encountered upon administration according to the method of the present invention. Thus, it would not have been reasonably expected that there would be differences in PK and / or PD depending on pH changes caused by different fasting regimens.
[0383] The condition of "at least 10 hours of night fasting, MAV administration + low-fat meal 30 minutes after MAV (consumption within 30')" showed greater absorption (higher Cmax) compared to the fasting state, but lower total exposure (AUC).
[0384] Summary statistics of plasma mavoric sarcophores parameters by treatment condition are below Table 5 It is presented in.
[0385] [Table 5]
[0386] Summary Statistics of Plasma Pharmacokinetic Parameters by Treatment Condition (Pharmacokinetic Analysis Set)
[0387]
[0388]
[0389]
[0390] pharmacokinetics conclusion
[0391] GMR: Geometric Mean Ratio; CI: Confidence Interval.
[0392] As a result of administering Maborixafor after at least 10 hours of nighttime fasting, the geometric mean (geoCV%) C maxis 2251 ng / mL (34.7%), geometric mean (geoCV%) AUC 0-inf is 9793 h*ng / mL (45.3%) and geometric mean (geoCV%) AUC 0-last It was 9156 h*ng / mL (45.9%).
[0393] When a high-fat meal (consumed within 30 minutes) is followed by at least 10 hours of nighttime fasting and a 400 mg dose of Maborixapor (Condition B) is administered, the bioavailability of Maborixapor decreases compared to the fasting condition (Condition A):
[0394] C max The GMR (90% CI) for was 33.800 (27.05, 42.23).
[0395] AUC 0-inf The GMR (90% CI) for was 44.677 (38.99, 51.19).
[0396] AUC 0-last The GMR (90% CI) for was 45.194 (39.33, 51.93).
[0397] When a low-fat meal (consumed within 30 minutes) is followed by at least 10 hours of nighttime fasting and a dose of 400 mg of Maborixapor (Condition C) is administered, the bioavailability of Maborixapor decreases compared to the fasting condition (Condition A):
[0398] C max The GMR (90% CI) for was 45.251 (36.07, 56.77).
[0399] AUC 0-inf The GMR (90% CI) for was 48.861 (42.71, 55.90).
[0400] AUC 0-last The GMR (90% CI) for was 48.074 (41.72, 55.40).
[0401] When a low-fat meal (Condition D) is consumed 30 minutes after administering Maborixafor following at least 10 hours of nighttime fasting, the bioavailability of Maborixafor does not change compared to the fasting condition (Condition A):
[0402] C max The GMR (90% CI) for was 114.125 (90.67, 143.65). It is slightly outside the equivalence limit of 70-143%.
[0403] AUC 0-inf The GMR (90% CI) for was 82.144 (71.54, 94.31).
[0404] AUC 0-last The GMR (90% CI) for was 83.277 (72.13, 96.15).
[0405] When Maborixafor is administered in the evening 2 hours after a high-fat meal (consumed within 30 minutes) following at least 4 hours of afternoon fasting (Condition E), the bioavailability of Maborixafor decreases compared to the fasting condition (Condition A):
[0406] C max The GMR (90% CI) for was 41.085 (32.83, 51.42).
[0407] AUC 0-inf The GMR (90% CI) for was 63.446 (55.35, 72.73).
[0408] AUC 0-last The GMR (90% CI) for was 61.430 (53.38, 70.69).
[0409] When Maborixafor is administered after at least 4 hours of afternoon fasting (Condition F), the bioavailability of Maborixafor decreases compared to the fasting condition (Condition A):
[0410] C maxThe GMR (90% CI) for was 56.514 (45.19, 70.68).
[0411] AUC 0-inf The GMR (90% CI) for was 76.057 (66.61, 86.84).
[0412] AUC 0-last The GMR (90% CI) for was 76.507 (66.51, 88.00).
[0413] Administering a single dose of Maborixafor after a low-fat or high-fat meal following at least 10 hours of nighttime fasting (Conditions C and B, respectively) reduces Maborixafor exposure by approximately 20% to 40% compared to administering Maborixafor in the afternoon after a 4-hour fast (Condition F). Administering Maborixafor after nighttime fasting and having a low-fat meal 30 minutes later (Condition D) reduces exposure to C compared to administering it in the afternoon after a 4-hour fast (Condition F). max It increases by approximately 100%. When Maborixafor is administered in the evening 2 hours after a high-fat meal (consumed within 30 minutes) following at least 4 hours of afternoon fasting (Condition E), Cmax decreases by 27% compared to administration in the afternoon after 4 hours of fasting (Condition F).
[0414] Even if Maborixafor is administered after a 10-hour night fast and a meal is eaten 30 minutes after administration, the bioavailability of Maborixafor does not change compared to the fasting condition (no food intake for 4 hours after administration following a 10-hour night fast). However, when a meal was provided before the administration of Maborixafor, the bioavailability of Maborixafor decreased compared to the fasting condition.
Claims
Claim 1 A method for treating neutropenia in a patient comprises the step of orally administering mavorixafor or a pharmaceutically acceptable salt thereof to the patient, wherein: (i) The patient has fasted from all food and beverages except water for at least 7 hours prior to the administration of mavorixafor or its pharmaceutically acceptable salt, and has continued to fast for at least 30 minutes after administration; and (ii) A method in which maborixafor or a pharmaceutically acceptable salt thereof is administered once daily in a dose of about 100 mg to about 800 mg. Claim 2 A method according to claim 1, wherein if the patient is at least 18 years of age, the patient is administered about 400 mg of mavorixafor or a pharmaceutically acceptable salt thereof per day; if the patient is 12 to 17 years of age and weighs at least 50 kg, the patient is administered about 400 mg of mavorixafor or a pharmaceutically acceptable salt thereof per day; or if the patient is 12 to 17 years of age and weighs less than 50 kg, the patient is administered about 200 mg of mavorixafor or a pharmaceutically acceptable salt thereof per day. Claim 3 In paragraph 1 or 2, the patient has fasted for at least 10 hours prior to administration of maborixaphor or a pharmaceutically acceptable salt thereof. Claim 4 A method according to paragraph 1 or 2 in which the patient fasts for at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, or at least 16 hours prior to administration of maborixafor or a pharmaceutically acceptable salt thereof. Claim 5 In paragraph 1 or 2, the patient fasts for 8 to 16 hours prior to administration of maborixaphor or a pharmaceutically acceptable salt thereof. Claim 6 A method according to any one of paragraphs 1 to 5, wherein the patient continues to fast for at least 45 minutes, at least 1 hour, at least 1.5 hours, or at least 2 hours after administration. Claim 7 A method in which, in any one of paragraphs 1 to 5, the patient continues to fast for 30 minutes to 4 hours after administration. Claim 8 A method according to any one of claims 1 to 7, wherein the patient has an absolute neutrophil count (ANC) of less than 1,500 cells / μL for at least 3 months prior to initiating treatment with maborixafor or a pharmaceutically acceptable salt thereof. Claim 9 A method according to any one of claims 1 to 7, wherein the patient has an absolute neutrophil count (ANC) of less than 1,000 cells / μL for at least 3 months prior to initiating treatment with maborixafor or a pharmaceutically acceptable salt thereof. Claim 10 A method according to any one of claims 1 to 7, wherein the patient has an absolute neutrophil count (ANC) of less than 600 cells / μL for at least 3 months prior to initiating treatment with maborixafor or a pharmaceutically acceptable salt thereof. Claim 11 A method according to any one of claims 1 to 7, wherein the patient has an absolute neutrophil count (ANC) of less than 500 cells / μL before starting treatment with maborixaphor or a pharmaceutically acceptable salt thereof. Claim 12 A method according to any one of claims 1 to 7, wherein the patient has an absolute neutrophil count (ANC) of less than 400 cells / μL before starting treatment with maborixafor or a pharmaceutically acceptable salt thereof. Claim 13 A method according to any one of claims 1 to 12, wherein the patient has congenital neutropenia, acquired primary autoimmune neutropenia, or chronic idiopathic neutropenia before starting treatment with maborixafor or a pharmaceutically acceptable salt thereof. Claim 14 In paragraph 13, the patient has congenital neutropenia. Claim 15 In paragraph 13, the patient has primary acquired neutropenia. Claim 16 In paragraph 15, primary acquired neutropenia is a method in which primary autoimmune neutropenia. Claim 17 In paragraph 15, primary acquired neutropenia is idiopathic. Claim 18 A method according to any one of claims 1 to 17, wherein the patient had neutropenia for at least 6 months prior to starting treatment with maborixafor or a pharmaceutically acceptable salt thereof. Claim 19 In paragraph 13, neutropenia is not caused by drugs, active or recent infection or malignancy. Claim 20 In paragraph 13, the neutropenia is severe congenital neutropenia (SCN) associated with ELANE, CSF3R, CXCR2, or WAS mutations. Claim 21 In paragraph 18, neutropenia is a non-cyclic method. Claim 22 A method according to any one of claims 1 to 13, wherein neutropenia is associated with an extrahematological symptom selected from Barth syndrome, Cohen syndrome, G6PC3 and Kostmann disease; associated with glycogen storage disease 1b (GSD1b); or the patient has Schwachman-Diamond syndrome. Claim 23 A method according to any one of claims 1 to 22, wherein the patient has an increased risk of infection selected from respiratory infection, otitis media, stomatitis, urinary tract infection, pyelonephritis, skin abscess, cellulitis, and sepsis before initiating treatment with maborixaphor or a pharmaceutically acceptable salt thereof. Claim 24 In any one of paragraphs 1 through 22, the patient has experienced at least 7 infections in the past year or at least 2 infections requiring hospitalization in the past year. Claim 25 In any one of paragraphs 1 through 24, the method is a method that results in the following improvements: a. b. Frequency, severity, duration, or time to the next infection Occurrence and / or disappearance of oral ulcers; c. The onset and / or disappearance of gingivitis; or any combination of the foregoing. Claim 26 A method according to any one of claims 1 to 25, wherein the method achieves an absolute neutrophil count (ANC) of at least 500 cells / μL and / or an absolute leukocyte count (ALC) of at least 1000 cells / μL. Claim 27 In any one of claims 1 to 26, the method achieves an absolute neutrophil count (ANC) of about 500 cells / μL to 3,000 cells / μL. Claim 28 A method according to any one of claims 1 to 25, wherein the method achieves an absolute neutrophil count (ANC) of about 500 cells / μL to 3,000 cells / μL and an absolute leukocyte count (ALC) of about 1,000 to 3,000 cells / μL. Claim 29 A method according to any one of claims 1 to 25, wherein the method achieves an absolute neutrophil count (ANC) of at least 1,500 cells / μL in at least 60% of the evaluation, or achieves at least a twofold increase in ANC when the patient has an ANC level of 500 cells / μL or less prior to treatment. Claim 30 In any one of claims 1 to 29, the method is an increased maximum plasma concentration (maximum plasma concentration, C) of mavoricsapor compared to mavoricsapor administered to a non-fasting patient. max A method for providing ) or Area Under the Curve (AUC). Claim 31 In any one of claims 1 to 30, the method has a maximum plasma concentration of at least 3700 μg / mL of maborixaphor (C max ) and / or area under the curve (AUC) over 24 hours at least 16,000 μg / mL 0-24 A method of providing ). Claim 32 In any one of claims 1 to 30, the method has a maximum plasma concentration of at least 4000 μg / mL of maborixaphor (C max ) and / or area under the curve (AUC) over 24 hours at least 17,000 μg / mL 0-24 A method of providing ). Claim 33 In any one of claims 1 to 30, the method has a maximum plasma concentration of at least 4200 μg / mL of maborixaphor (C max ) and / or area under the curve (AUC) over 24 hours at least 18,000 μg / mL 0-24 A method of providing ). Claim 34 In any one of claims 1 to 30, the method has a maximum plasma concentration of maborixaphor of about 3,700 to about 7,500 μg / mL (C max ) and / or area under the curve (AUC) over 24 hours at about 16,000 to 25,000 μg / mL 0-24 A method of providing ). Claim 35 In any one of claims 1 to 30, the method is an average maximum plasma concentration of about 3,700 to about 7,500 μg / mL of maborixaphor (C) in a group of two or more patients. max ) and / or average area under the curve (AUC) over 24 hours of about 16,000 to 25,000 μg / mL 0-24 A method of providing ). Claim 36 In any one of claims 1 to 30, the method is an average maximum plasma concentration of mavorixafor (C) in a group of two or more patients that is about 15% to 30% greater than that in a comparable group of two or more patients administered mavorixafor in a non-fasting state. max ) providing; and / or the method provides an average area under the curve (AUC) over 24 hours that is about 15% to 30% larger than that in a comparable group of two or more patients administered mavorixafor in a non-fasting state. 0-24 A method of providing ). Claim 37 A method in which, in any one of paragraphs 1 to 36, the patient receives treatment using G-CSF, GM-CSF, or any one of these variants. Claim 38 In paragraph 37, the patient is administered a first dose of G-CSF, GM-CSF, or any one of these variants once a day. Claim 39 In paragraph 38, the method wherein the first dose of G-CSF, GM-CSF, or any one of these variants is about 5 mcg / kg. Claim 40 In any one of paragraphs 1 through 39, the patient is about 10 2 A method having an endogenous G-CSF concentration of pg / mL or less. Claim 41 In any one of paragraphs 1 through 39, the patient is about 10 2 pg / mL to 10 4 Method for having an endogenous G-CSF concentration of pg / mL. Claim 42 In any one of paragraphs 1 through 39, the patient is about 10 5 A method having an endogenous G-CSF concentration of pg / mL or higher. Claim 43 In any one of paragraphs 1 through 39, the patient has a genetic abnormality associated with WHIM syndrome ( CXCR4 A method that does not have a gene with a gain-of-function mutation.
